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Abstract
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In recent years, a new neurodegenerative tauopathy labeled Chronic Traumatic Encephalopathy
(CTE), has been identified that is believed to be primarily a sequela of repeated mild traumatic
brain injury (TBI), often referred to as concussion, that occurs in athletes participating in contact
sports (e.g. boxing, football, football, rugby, soccer, ice hockey) or in military combatants,
especially after blast-induced injuries. Since the identification of CTE, and its neuropathological
finding of deposits of hyperphosphorylated tau protein, mechanistic attention has been on lumping
the disorder together with various other non-traumatic neurodegenerative tauopathies. Indeed,
brains from suspected CTE cases that have come to autopsy have been confirmed to have deposits
of hyperphosphorylated tau in locations that make its anatomical distribution distinct for other
tauopathies. The fact that these individuals experienced repetitive TBI episodes during their
athletic or military careers suggests that the secondary injury mechanisms that have been
extensively characterized in acute TBI preclinical models, and in TBI patients, including
glutamate excitotoxicity, intracellular calcium overload, mitochondrial dysfunction, free radicalinduced oxidative damage and neuroinflammation, may contribute to the brain damage associated
with CTE. Thus, the current review begins with an in depth analysis of what is known about the
tau protein and its functions and dysfunctions followed by a discussion of the major TBI
secondary injury mechanisms, and how the latter have been shown to contribute to tau pathology.
The value of this review is that it might lead to improved neuroprotective strategies for either
prophylactically attenuating the development of CTE or slowing its progression.
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1. Introduction
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Chronic traumatic encephalopathy (CTE) is classified as a neurodegenerative tauophathy
(McKee et al., 2016). In addition to CTE several other tauopathies exist including
Alzheimer's disease (AD), frontotemporal dementia (FTD), progressive supra nuclear palsy
(PSP), corticobasal degeneration, Pick's disease, and argyrophilic grain disease (Lee and
Leugers, 2012). One defining characteristic of tauopathies is hyperphosphorylation of the
protein tau. Once hyperphosphorylated, tau assumes a tightly folded confirmation,
increasing susceptibility to aggregation, conformational change, filament assembly,
polymerization into paired helical filaments, and bundling of paired helical filaments into
neurofibrillary tangles and neuropil threads (Mietelska-Porowska et al., 2014).
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Clinically, CTE is characterized by cognitive, behavioral, and/or mood dysfunction, with the
possible accompaniment of motor symptoms (Montenigro et al., 2014). Unfortunately, the
current incidence and prevalence of CTE is unknown (Kiernan et al., 2015) because
although CTE can be suspected clinically, a definitive diagnosis can only be made postmortem (McKee et al., 2016). Recently, a consensus meeting was held to define the
neuropathological criteria of CTE, and concluded that a CTE diagnosis should be based
upon identification of an irregular pattern of abnormally hyperphosphorylated tau
accumulations in astrocytes and neurons located around small blood vessels and at the
depths of cortical sulci (McKee et al., 2016). Additional non-specific, but supportive features
of CTE, include hippocampal tangles, neurofibrillary tangles in the subcortical nuclei, and
TAR DNA-binding protein 43 (TDP-43) reactivity in the temporal cortex, hippocampus and
amygdala (McKee et al., 2016). However, in reaching the consensus, definition other
neuropathologic characteristics of CTE were not addressed including gliosis, inflammation,
hemosiderin deposition, and the presence of comorbid pathologies such as Aβ and αsynuclein deposition (McKee et al., 2016). Although the neuropathologic criteria for CTE
have now been defined, identification of CTE as a unique entity remains controversial for
several reasons including reliance on retrospective case reports subject to selection bias for
identification of cases (Maroon et al., 2015), as well a lack of prospective and epidemiologic
studies (McCrory et al., 2013). Indeed, the clinical diagnostic criteria of CTE vs. other
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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neurodegenerative disorders (e.g. AD) for which the history of one or more traumatic brain
injuries is an established risk factor is still being intensely debated.
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Nevertheless, to date, CTE pathology has only been identified in individuals with a history
of traumatic brain injury (TBI) (McKee et al., 2016). CTE pathology has been observed in
the brains of military personnel who have sustained blast injuries, and in athletes who
participate in sports where the risk of sustaining repetitive head injuries is high including
boxing, football, soccer, hockey and rugby (Goldstein et al., 2012; Kiernan et al., 2015;
McKee et al., 2009; McKee and Robinson, 2014; McKee et al., 2013; Omalu et al., 2011b;
Omalu et al., 2006; Omalu et al., 2005). Although there are several tauopathies, the
pathoanatomic location of tau deposition in CTE makes it distinct from the others (Kiernan
et al., 2015; McKee et al., 2016). However, the neuronal tau found in CTE does share a
similar profile in regard to isoform ratio and phosphorylation state as the tau in AD (Kiernan
et al., 2015; McKee et al., 2014; Schmidt et al., 2001). CTE and AD share other similarities;
brain injury also increases the risk of developing AD (Guo et al., 2000; Nemetz et al., 1999;
Plassman et al., 2000). In fact both pathologic tau (Ikonomovic et al., 2004; Johnson et al.,
2012; Uryu et al., 2007) and Aβ deposition (Johnson et al., 2012; Reynolds et al., 2005;
Reynolds et al., 2006) are seen following a single severe TBI.

Author Manuscript

Although advancements have been made in defining the core neuropathological features of
CTE, much about CTE is still unknown. Similar to brain injury itself, CTE is heterogeneous
both in its supporting neuropathological features (McKee et al., 2016) and in its clinical
presentation. Clinically, CTE is suspected of having at least two subtypes, a younger onset
subtype predominated by behavior and mood symptoms but with minimal cognitive or motor
impairment, and an older onset subtype characterized by cognitive impairment and motor
dysfunction (Stern et al., 2013). However, up to four clinical subtypes have been proposed
(Montenigro et al., 2014).
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The pathophysiologic processes which lead to the development of CTE, the main
characteristic of which is pathologic tau deposition, are not well understood. Although
repetitive TBI has been singled out as a major etiologic factor in CTE and brain injury is
considered necessary for its development (McKee et al., 2016), individuals who have
experienced repetitive TBI do not always go on to develop CTE (Hazrati et al., 2013; McKee
et al., 2013; Omalu et al., 2011a). Additional factors hypothesized to contribute to CTE
include environment, genetics and injury characteristics, e.g. age at injury, type and severity
of injury, number of hits, duration between injuries, etc. (Ojo et al., 2016) Although animal
models are being utilized to further characterize CTE and repetitive TBI, many have failed to
recapitulate the tau pathology seen in CTE or have required the use of transgenic mice
already predisposed to develop tau pathology (Ojo et al., 2016). Therefore, there is much
still to be elucidated regarding the progression of CTE following injury. However, despite
the paucity of information regarding how CTE tau pathology progresses over time, the tau
protein itself and processes that contribute to its dysfunction have been well characterized in
the literature, thanks in large part to AD, FTD and TBI models in which tauopathy is
a.commonly occurring pathology.

Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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In this review, which focuses on CTE, we attempt to integrate what is known about
canonical post-traumatic neurodegenerative processes and the tau protein in order to identify
mechanisms which could possibly lead to, or contribute to, chronic tau dysfunction
following TBI that might serve as pharmacological neuroprotective targets. We have chosen
to direct our attention to CTE because, by definition it is associated with the previous
occurrence of repetitive, and possibly singular TBI even though, a history of TBI is known
to be a risk factor for other neurodegenerative disorders that are involve the same secondary
post-TBI degenerative mechanisms. Thus, throughout the rest of this review, we consistently
mention what is known about the interaction of post-TBI secondary injury processes such as
mitochondrial dysfunction oxidative stress, intracellular calcium overload, etc., with the
pathogenesis of other neurodegenerative disorders as AD, that involve tauopathies that
appear to be somewhat pathologically distinct from CTE. While this review is mainly
directed at CTE, our literature review has revealed a rich interaction between acute post-TBI
secondary injury mechanisms and tauopathy development in general.

2. The Tau Protein – Functions and Dysfunctions
2.1 Functions

Author Manuscript

There are several detailed reviews that cover structure, function, and post-translational
modification of the tau protein (Fontaine et al., 2015; Lee and Leugers, 2012; Morris et al.,
2011). Tau is encoded for by the MAPT gene found on chromosome 17, a gene that is
mutated in several tauopathies including FTD (Ferrari et al., 2011) and PSP (Im et al., 2015).
In humans, alternative splicing generates six isoforms of tau containing either three (3R) or
four (4R) microtubule binding repeats (Goedert and Jakes, 1990), leading to formation of
isoforms with differing characteristics (Lee and Leugers, 2012). Additional heterogeneity
exists in the n-terminal region as well (Goedert and Jakes, 1990). As stated previously, the
neuronal tau of CTE has a similar isoform ratio and phosphorylation state as the tau of AD
(Kiernan et al., 2015; McKee et al., 2014; Schmidt et al., 2001). AD is reported to have a 2:1
ratio of 4R:3R tau (Chen et al., 2010b; Conrad et al., 2007; Ginsberg et al., 2006), a shift
from the equal 4R:3R ratio found in healthy adult brains (Goedert and Jakes, 1990; Kosik et
al., 1989).
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The most well-known function of tau is its ability to bind microtubules, which promotes
microtubule assembly and stabilization (Fontaine et al., 2015; Lee and Leugers, 2012;
Morris et al., 2011). However, tau has several other functions, including axonal transport
(Cuchillo-Ibanez et al., 2008; Lee and Leugers, 2012; Morris et al., 2011), regulation of
actin and neurite outgrowth (Lee and Leugers, 2012; Morris et al., 2011), and regulation of
signaling pathways (Morris et al., 2011). Tau can associate with heat shock proteins,
chaperone proteins involved in the tau degradation pathway (Fontaine et al., 2015; Lee and
Leugers, 2012), and although tau is primarily found associated with the cytoskeleton of
axons, it can also localize to the nucleus, as well as interact with the plasma membrane and
post-synaptic density (Fontaine et al., 2015; Lee and Leugers, 2012; Morris et al., 2011).
The binding of tau to microtubules can be regulated by the tau phosphorylation state, and
phosphorylation of tau within the microtubule binding sites decreases the ability of tau to
bind microtubules (Fontaine et al., 2015). Similarly, several of the tau mutations utilized in
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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transgenic tau mice, such as P301L and P301S, function to decrease binding of tau to
microtubules and can lead to decreases in microtubule assembly (Fontaine et al., 2015;
Hasegawa et al., 1998; Iovino et al., 2014). Several protein kinases and phosphatases
regulate tau phosphorylation, and thus its ability to interact with microtubules (Fontaine et
al., 2015; Martin et al., 2013; Morris et al., 2011).
2.2 Dysfunctions
One characteristic feature of tauopathies, such as CTE and AD, is tau hyperphosphorylation,
where phosphorylation of tau at specific residues occurs as an ordered process, leading to
tau aggregation (Alonso et al., 2001; Fontaine et al., 2015; Jeganathan et al., 2008; Morris et
al., 2011) and oligomer formation (Tepper et al., 2014). In addition to tauopathies, TBI is
also capable of inducing tau hyperphosphorylation (Ikonomovic et al., 2004; Uryu et al.,
2007; Yang et al., 2016).
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In addition to phosphorylation other post-translational modifications to tau occur such as
acetylation, glycosylation, sumolyation, ubiquitination, polyamination, oxidation, nitration,
isomerization and truncation (Fontaine et al., 2015; Morris et al., 2011). Many of these posttranslational modifications have been implicated in the formation of pathologic tau. For
example, oxidation of tau induces cross-linkages and aggregation (Reynolds et al., 2005) and
nitration of tau decreases microtubule binding and assembly (Reynolds et al., 2005).
Isomerization of pThr231 tau to the cis isoform attenuates tau dephosphorylation, decreases
microtubule binding, and promotes aggregation (Wang and Zhang, 2015), and proteolytic
cleavage of tau by calpain or caspase (Liu et al., 2011) can result in formation of truncated
tau species which are prone to aggregation (Fontaine et al., 2015).
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The mechanisms regarding tau toxicity in neurodegenerative disease remain controversial
(Morris et al., 2011), with both loss of function and gain of function theories being proposed
(Trojanowski and Lee, 2005). However, although hyperphosphorylated tau results in
decreased binding of tau to microtubules, several studies indicate that knock-down of tau
results in normal behavioral phenotypes, synaptic transmission and microtubule stability,
without compensatory increases in other microtubule-binding proteins, such as MAP1 or
MAP2, suggesting that tau toxicity may not be a direct result of loss of function (Morris et
al., 2011). Rather, the toxicity associated with pathologic tau may in part be due to tau
mislocalization and/or dysfunctional axonal transport. The majority of tau is localized to
axons (Morris et al., 2011); however, tau hyperphosphorylation results in redistribution of
tau from the axon to the somatodendritic compartment, an effect which is sufficient to
impair synaptic function (Hoover et al., 2010), and several studies have shown that
pathologic tau isoforms impair fast axonal transport (Lee and Leugers, 2012).
Evidence has also accumulated suggesting that tau oligomers, i.e. pre-filamentous tau
aggregates, are more toxic than filamentous or monomeric tau (Spires-Jones et al., 2011).
For example, injection of human tau oligomers into mouse brains results in impaired
memory consolidation, as well as synaptic and mitochondrial dysfunction, whereas
administration of tau monomers or fibrils does not (Lasagna-Reeves et al., 2011), while
repression of human tau in transgenic mice results in attenuation of neuronal loss and
cognitive impairment despite continued increases in neurofibrillary tangle formation
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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(Santacruz et al., 2005). Similarly, in a drosophila model of tauopathy, neurodegeneration
can still be seen in the absence of neurofibrillary tangle formation (Wittmann et al., 2001).
Interestingly, It has been hypothesized that one reason oligomeric tau is able to accumulate
in tauopathies is due to the fact that both oligomeric tau and cleaved forms of tau, which
have an increased propensity for aggregation compared to full-length tau, are preferentially
degraded via autophagy (Chesser et al., 2013), a pathway reported to be defective in
tauopathies (Piras et al., 2016) and TBI (Sarkar et al., 2014). Although proteasome
dysfunction, the mechanism which preferentially degrades monomeric tau, has also been
reported to occur following TBI due to mechanisms such as oxidative stress (Bader and
Grune, 2006; Weih et al., 2001; Yao et al., 2008), monomeric full-length tau has a decreased
propensity to aggregate compared to cleaved tau (Chesser et al., 2013) and is less toxic than
oligomeric tau (Spires-Jones et al., 2011).
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Tau is considered to have prion-like properties (Alonso et al., 2016; Medina and Avila,
2014), which likely contribute to intracellular, intraregional, and trans-synaptic spread of
pathologic tau (Liu et al., 2012; Medina and Avila, 2014). Tau can be secreted from neurons
in its naked form or within exosomes or membrane vesicles (Chai et al., 2012; Medina and
Avila, 2014; Saman et al., 2012; Simon et al., 2012). In healthy neurons the release of tau is
induced by neuronal activity, however, neuronal activity is altered following TBI (Carron et
al., 2016) and in tauopathy brains (Pooler et al., 2013), likely resulting in abnormal tau
release (Pooler et al., 2013). Additionally, both c-terminal proteolytic cleavage of tau and tau
overexpression are capable of enhancing tau secretion (Medina and Avila, 2014; Plouffe et
al., 2012; Simon et al., 2012). In-vitro, extracellular tau is known to be toxic (Gomez-Ramos
et al., 2006; Medina and Avila, 2014), through a mechanism which may involve increases in
intracellular calcium levels via tau stimulation of muscarinic receptors (Gomez-Ramos et al.,
2008), and in further support of the toxic oligomeric theory, only extracellular tau
aggregates, not tau monomers, are taken up by cells (Alonso et al., 2016; Frost et al., 2009;
Wu et al., 2013). Once tau is secreted, the extracellular tau has the ability to enhance tau
pathology. For example, transplanting TBI induced tau oligomers into naive brains of hTau
transgenic mice results in oligomeric spread of tau and accelerated cognitive impairment
(Gerson et al., 2016), secreted tau fibrils are capable of inducing transcellular misfolding and
tau aggregation (Kfoury et al., 2012), and hyperphosphorylated tau is capable of forming
filaments and tangles with non-phosphorylated tau (Alonso et al., 1996). Therefore, it is
possible that in non-familial tauopathies, such as CTE, an initial event, such as repetitive
TBI, triggers a misfolding cascade which can then be transmitted in a prion-like manner
(Morales et al., 2015).
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3. Traumatic Brain Injury - Pathophysiological Mechanisms
Although the specific mechanisms by which repetitive TBI can lead to CTE or by which a
single severe TBI can lead to AD are still being elucidated, much of the pathology that
occurs in tauopathies is paralleled in TBI. TBIs range from mild to severe, with at least 2.5
million TBIs occurring in the United States annually (Faul M, 2010), the majority of which
are classified as mild (Holm et al., 2005). However, these numbers are underestimates
because mild TBIs often go unreported, especially in sports and military communities
(Jordan, 2013; Marion et al., 2011), populations which are at additional risk for sustaining
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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repeat injuries. In fact, it is estimated that sports-related TBIs alone occur at a rate of 3.8
million annually (Langlois et al., 2006).
3.1 Primary Injury Mechanisms
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TBI consists of a primary injury followed by a secondary injury cascade. The primary injury
occurs immediately and is caused by external forces, such as a direct impact, rapid
acceleration/deceleration, or blast a wave. Primary injury can result in contusion,
hemorrhage, ischemia, shearing and straining of axons and blood vessels, and diffuse axonal
injury from the mechanical insult (Maas et al., 2008; McAllister, 2011; Weber, 2012). Of
important relevance to CTE, which consists of tau pathology located at the depths of cortical
sulci and around blood vessels, are deceleration/acceleration and blast forces (McKee et al.,
2016). Deceleration/acceleration forces are particularly damaging to long white matter tracts
and the grey-white matter junctions of the cerebral cortex (McAllister, 2011), and blast
injury has been reported to damage perivascular neural tissue due to transmission of pressure
waves throughout the cerebral vasculature (McAllister, 2011).
3.2 Secondary Injury Mechanisms
Cellular strain and deformation caused by the primary injury results in membrane
depolarization, mechanoporation of membranes, ionic imbalances, and neurotransmitter
release, resulting in initiation of the secondary injury cascade, a process which occurs hours
to weeks following injury (Maas et al., 2008; McAllister, 2011), and is heavily influenced by
alterations in calcium homeostasis (Weber, 2012).
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3.2.1 Intracellular Calcium Overload, Oxidative Damage and Mitochondrial
Dysfunction—Activation of calcium channels by high levels of extracellular glutamate
following injury, along with activation of voltage-gated calcium channels and membrane
leakage lead to large increases in intracellular calcium (Weber, 2012). As essential regulators
or calcium homeostasis (Rizzuto et al., 2000; Rizzuto et al., 1999) mitochondria buffer the
increases in intracellular calcium following TBI (Lifshitz et al., 2003; Xiong et al., 1997).
Increases in mitochondrial calcium lead to decreased respiration and increased generation of
reactive oxygen and nitrogen species (ROS/RNS) (Fiskum, 2000; Sullivan et al., 2005).
Following TBI, as the electron transport chain becomes impaired, single electrons leak from
complex I, generating superoxide radicals (O2•-), which rapidly react the nitric oxide (NO•)
generated by calcium activated mitochondrial nitric oxide synthase (mtNOS), forming
peroxynitrite (PN) anion (ONOO-) (Bringold et al., 2000; Radi et al., 2002). Protonation of
ONOO- results in peroxynitrious acid (ONOOH) which decomposes into nitrogen dioxide
(NO•2) and hydroxyl (OH•) radicals. Alternatively, ONOO- can react with carbon dioxide to
form nitrosoperoxocarbonate (ONOOCO2-) which decomposes into the radicals NO•2 and
(CO•-3) (Bains and Hall, 2012; Hall et al., 2010). PN is demonstratively increased following
TBI (Deng et al., 2007; Hall et al., 2004; Hall et al., 2012; Singh et al., 2007) and because of
its unique diffusion radius, mitochondrial derived PN is capable of damaging multiple
cellular structures (Hall et al., 2010).
The highly reactive PN-derived radicals, NO•2, OH•, CO•-3, initiate lipid peroxidation (LP)
of polyunsaturated fatty acids, such as arachidonic acid, which are highly enriched in
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neurons and cellular and organelle membranes, forming lipid peroxyl radicals (Bains and
Hall, 2012; Hall et al., 2010). LP propagates throughout the membrane as lipid peroxyl
radicals react with adjacent polyunsaturated acids, and although lipid peroxidation is
considered to be a self-propagating process, it is also catalyzed by the presence of iron,
particularly in the acidic tissues of TBI (Hall et al., 2010). Following TBI, decreases in pH
cause iron to be released from the iron storage proteins, ferritin and transferritin, and
additional iron is released from the hemoglobin deposited during hemorrhages and
microbleeds (Hall et al., 2010). Therefore, similar to tau deposition in CTE, iron-catalyzed
LP may be enhanced near the vasculature following TBI. LP terminates with formation of
neurotoxic aldehydes, such as 4-hydroxynonenal (4-HNE) and 2-propenal (acrolein). Both
LP and its derivatives, 4-HNE and acrolein, are well known to be increased following TBI
(Bayir et al., 2007; Hall et al., 2004; Mustafa et al., 2010; Mustafa et al., 2011; Singh et al.,
2013) (Cebak et al., 2016; Hill et al., Submitted).
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The neurotoxic aldehydes, 4-HNE and acrolein, covalently bind proteins via the amino acids
lysine, histidine, or cysteine, resulting in enzyme inhibition and protein dysfunction (Hall et
al., 2010; Petersen and Doorn, 2004; Stevens and Maier, 2008). In addition to protein
dysfunction, neurotoxic aldehydes, ROS/RNS and lipid peroxyl radicals are capable of
inducing DNA damage to both nuclear and mitochondrial DNA (Dalleau et al., 2013; Hall et
al., 2010). As a major site of PN formation, mitochondria are particularly susceptible to
attack by LP-derived neurotoxic aldehydes. Binding of 4-HNE and acrolein to mitochondria
results in extensive mitochondrial dysfunction through impairment of mitochondrial
respiration and enhanced generation of ROS/RNS (Singh et al., 2013; Vaishnav et al., 2010)
(Cebak et al., 2016; Hill et al., Submitted; Miller et al., 2013; Picklo et al., 1999; Picklo and
Montine, 2001). Following TBI, the mitochondrial dysfunction induced by LP-derived
neurotoxic aldehydes and increased intra-mitochondrial calcium concentrations leads to
formation of the mitochondrial permeability transition pore (mPTP) (Bringold et al., 2000;
Hansson et al., 2008; Sullivan et al., 2005). Opening of the mPTP results in collapse of the
mitochondrial membrane potential, loss of ATP production, mitochondrial swelling, rupture
of the outer mitochondrial membrane and release of calcium and cytochrome c into the
cytosol (Galluzzi et al., 2009; Sullivan et al., 2005).
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3.2.2 Calcium-Mediated Proteolytic Degradation—Extrusion of calcium back into
the cytosol leads to neurodegeneration, necrosis, and activation of the calcium-dependent
cysteine protease, calpain, which is capable of breaking down a variety of cytoskeletal
proteins including MAP2, spectrin and tau (Galluzzi et al., 2009; Kampfl et al., 1997;
Sullivan et al., 2005; Wang, 2000). In fact, calpain-cleaved αII-spectrin breakdown products
are frequently used to assess post-TBI axonal damage and neuroprotection following TBI
(Bains et al., 2013; Deng-Bryant et al., 2008; Deng et al., 2007; Mbye et al., 2009; Miller et
al., 2014; Mustafa et al., 2011; Saatman et al., 1996). Similarly, mitochondrial release of
cytochrome c leads to activation of the protease caspase-3 and induction of apoptosis
(Galluzzi et al., 2009; Sullivan et al., 2005; Wang, 2000).
One effect of cytoskeletal degradation following TBI is impairment of axonal transport.
Following injury, axonal transport of amyloid precursor protein (APP), the precursor to Aβ,
a pathologic protein found in the tauopathy, AD, and some cases of CTE, is impaired and
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
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results in accumulations of APP in axonal varicosities and bulbs of damaged neurons; as
such, the accumulation of APP following TBI is often used as a marker for traumatic axonal
injury (Chauhan, 2014). In addition to cytoskeletal degradation, protein accumulation
following TBI can also occur due to proteasomal dysfunction (Yao et al., 2008). In
particular, the proteasome is responsible for the degradation of oxidatively damaged
proteins, however, it is also subject to oxidative stress-induced impairment itself (Bader and
Grune, 2006; Weih et al., 2001; Yao et al., 2008). In addition to protein accumulation
following injury, impairment of axonal transport also leads to somatodendritic accumulation
of organelles, such as the mitochondria (Kilinc et al., 2008), although, impairment of
mitochondrial dynamics following TBI is complex and includes additional processes such as
alterations in fission and fusion (Fischer et al., 2016).
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Following injury, the endoplasmic reticulum (ER) also functions to regulate calcium
homeostasis (Weber, 2012). Increases in ER stress are reported to occur in both single
(Begum et al., 2014; Krajewska et al., 2011; Larner et al., 2004; Logsdon et al., 2014) and
repetitive TBI (Lucke-Wold et al., 2016). In fact, calcium release from the ER has been
hypothesized to be toxic to neurons and white matter tracts (Weber, 2012). In addition to
regulation of intracellular calcium stores, the ER is involved in protein folding and quality
control of misfolded proteins and protein aggregates through a process termed, the unfolded
protein response (UPR) (Hoozemans and Scheper, 2012). Therefore, in addition to calciuminduced pathology, ER stress can also lead to several additional aspects of cellular
dysfunction, including inhibition of protein synthesis (Doutheil et al., 1997), apoptosis
(Nakagawa et al., 2000), accumulation of protein aggregates (Hoozemans and Scheper,
2012), and activation of the tau kinase, GSK-3β (Song et al., 2002).
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3.2.3 Neuroinflammation—Another important contributory factor to the pathology that
occurs following TBI is inflammation. Inflammation has been observed acutely following
TBI in both severe and mild injury, an effect which is amplified in mild TBI by repeated
injury (Collins-Praino and Corrigan, 2016). Following injury, resident immune cells, such as
astrocytes and microglia, are activated by damaged tissue and cellular debris (Collins-Praino
and Corrigan, 2016; Karve et al., 2016), but can also be activated by other mechanisms such
as ROS/RNS (Collins-Praino and Corrigan, 2016). Additionally, peripheral immune cells are
recruited to the site of injury (Collins-Praino and Corrigan, 2016; Karve et al., 2016).
Immune cells are capable of releasing both pro-inflammatory and pro-survival cytokines and
chemokines; therefore, they are capable of serving both destructive and reparative roles
following injury (Collins-Praino and Corrigan, 2016; Karve et al., 2016). For example, the
microglial phenotype M1 is neurotoxic, while the microglial phenotype M2 is
neuroprotective (Karve et al., 2016). Chronic microglial activation has been observed
following both human and experimental TBI and has been linked to chronic
neurodegeneration (Faden and Loane, 2015). In fact, the neurotoxic M1 phenotype has been
shown to persist longer than the M2 phenotype following TBI (Collins-Praino and Corrigan,
2016; Kumar et al., 2016; Wang et al., 2013a) Furthermore, some studies have demonstrated
that persistent neuroinflammation can occur decades following severe TBI or repetitive
concussion (Collins-Praino and Corrigan, 2016; Coughlin et al., 2015; Ramlackhansingh et
al., 2011). Physiologically, one explanation for the persistence of neuroinflammation
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following repetitive TBI focuses on microglial priming. Microglial priming is a process in
which microglia develop exaggerated immune responses and decreased activation thresholds
following an insult such as TBI; therefore, neuroinflammation can be chronically
exacerbated upon additional TBIs or systemic inflammation (Collins-Praino and Corrigan,
2016).
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3.2.4 Tau Phosphorylation—In direct relation to CTE, TBI also results in increased
levels of total and phosphorylated tau. In human TBI, injury severity is correlated with
increased tau phosphorylation, increased activity of the tau kinase GSK-3β, and decreased
activity of the tau phosphatase, PP2A, (Yang et al., 2016). Tau pathology has been reported
following cases of single severe TBI (Ikonomovic et al., 2004; Johnson et al., 2012; Uryu et
al., 2007), in patients whom have died within six months of sustaining a concussion (McKee
et al., 2014), and in young military veterans with a history of blast exposure (McKee and
Robinson, 2014). Therefore, there is not only increasing interest in investigating the
development of CTE-like tau pathology in animal models of single and repetitive TBI, but
also in the development of tau as a biomarker for TBI (Section 5. Tau – A Biomarker for
TBI). Figure 1 hypothesizes the possible contribution of single, or perhaps multiple,
pathophysiological mechanisms to the development of CTE.

4. The Role of Tau in Cellular Dysfunction
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The process in which acute TBI pathology develops into the chronic tau pathology seen in
the tauopathies CTE and AD remains to be established, however, the mechanisms that can
initiate formation of pathologic tau as well as the mechanisms by which tau can induce
cellular dysfunction parallel many of the secondary injury mechanisms of TBI, including
damage by ROS/RNS and LP-derived neurotoxic aldehydes, mitochondrial dysfunction, ER
stress, calpain and caspase activation, and inflammation.
4.1 Oxidative Stress
Oxidative stress is elevated in several tauopathies (Alavi Naini and Soussi-Yanicostas, 2015;
Castellani et al., 1995; Litvan, 2004; Martinez et al., 2008a). It is well known that in the
tauopathy AD, Aβ is capable of inducing oxidative stress, a process which is hypothesized
to be upstream of the formation of pathologic tau (Giraldo et al., 2014). Several studies
confirm both the ability of oxidative stress to induce tau pathology and the ability of
pathologic tau to induce oxidative stress, suggesting the possibility that in tauopathies such
as CTE a self-propagating cycle of pathologic tau formation and oxidative stress occurs and
leads to cellular dysfunction and neurodegeneration.
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In-vitro, oxidative stress can induce both increases in tau aggregation and phosphorylation.
Exposing tau isolated from bovine brain to iron-catalyzed oxidation results in dimerization,
polymerization and formation of tau filaments (Troncoso et al., 1993), and in primary rat
cortical neurons, oxidative stress (Fe2+/H2O2) increases tau phosphorylation by increasing
activity of the tau kinase, GSK-3β, an effect which is attenuated by the GSK-3β inhibitor,
lithium (Lovell et al., 2004). Interestingly, lithium also has the ability to attenuate tau
pathology in-vivo by decreasing GSK-3β dependent tau phosphorylation and aggregation in
transgenic tau mice (Perez et al., 2003). Additional in-vitro studies indicate that tau
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phosphorylation is also induced by chronic oxidative stress. Inhibiting glutathione synthase
in neuroblastoma cells induces a mild, chronic oxidative stress, which increases the activity
of the tau kinase, JNK, decreases the activity of the tau phosphatase, PP2A, and results in
increases in tau phosphorylation and tau aggregation (Su et al., 2010). Although these
studies indicate oxidative stress has the ability to induce tau phosphorylation in-vitro,
oxidative stress induced tau dephosphorylation has also been reported (Davis et al., 1997;
Galas et al., 2006; Olivieri et al., 2001; Zambrano et al., 2004). However, dephosphorylation
of tau following oxidative stress exposure seems to be limited to acute administration of
H2O2.
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In-vivo experiments also link tau phosphorylation to oxidative stress exposure. Transgenic
mice deficient for the mitochondrial antioxidant enzyme, SOD2, have increases in
mitochondrial-induced oxidative stress, which result in increased tau phosphorylation, an
effect which is attenuated by antioxidant administration (Melov et al., 2007). Additionally,
transgenic mice overexpressing the mutated form of human tau, P301S, show markers of
oxidative stress such as, increased mitochondrial protein carbonyls and decreased SOD2,
months prior to the appearance of tau hyperphosphorylation and tangle formation (Dumont
et al., 2011).
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While oxidative stress has a demonstrated ability to induce tau pathology, several studies
show that tau itself has the ability to induce oxidative stress. In-vitro, overexpressing tau
impairs trafficking of peroxisomes, organelles responsible for H2O2 detoxification and
results in increased susceptibility to H2O2-induced oxidative stress (Alavi Naini and SoussiYanicostas, 2015; Stamer et al., 2002). Tauopathy animal models also suggest the ability of
tau to induce oxidative stress. Cultured neurons obtained from transgenic rats expressing a
truncated form of human tau analogous to that found in AD have increased levels of ROS
and are more susceptible to oxidative stress, effects which are likely the result of decreased
numbers of mitochondria and abnormal mitochondrial distribution (Alavi Naini and SoussiYanicostas, 2015; Cente et al., 2006). Furthermore, transgenic mice overexpressing mutant
human tau, P301L, also show increased generation of ROS, another consequence of
mitochondrial dysfunction (Alavi Naini and Soussi-Yanicostas, 2015; David et al., 2005).
In summary, oxidative stress is well-established to occur in neurodegenerative tauopathies,
and there are several mechanisms by which oxidative stress can induce tau phosphorylation
and aggregation and by which pathologic tau can induce oxidative stress (Figure 2).
Therefore, a primary event capable of inducing either oxidative stress or tau dysfunction,
such as TBI, could set off a chronic and self-propagating cyclical cascade of oxidative stress
and pathologic tau formation.
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4.2 Peroxynitrite
Oxidative stress is often used as a broad term which encompasses a multitude of reactive
species, one specific reactive species being PN. The PN derived radical, NO•2, is capable of
nitrating tyrosine at the 3 position, thus forming 3-NT, a specific marker of PN-induced
cellular damage (Hall et al., 2010). 3-NT modified tau has been identified in a variety of
tauopathies, including AD, frontotemporal dementia, and Pick's disease (Horiguchi et al.,
2003; Smith et al., 1997).
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Peroxynitrite is capable of inducing tau dysfunction through both oxidation and nitration
mechanisms (Reynolds et al., 2005; Reynolds et al., 2006). In-vitro, cysteine oxidation of
tau by PN results in formation of disulfide crosslinks, tau oligomerization, and decreased
microtubule assembly (Landino et al., 2004). PN can also promote tau oligomerization
through addition of tyrosyl radicals which results in formation of 3,3′-dityrosine irreversible
crosslinks and stabilization of insoluble tau filament aggregates characteristic of late stage
paired helical filaments (PHF) (Reynolds et al., 2005; Reynolds et al., 2006). Furthermore,
although PN-derived NO•2 nitration of tau has been shown to inhibit tau polymerization
(Reynolds et al., 2005), 3-NT modification of tau does result in disrupted binding of tau to
microtubules and inhibition of tubulin assembly (Reynolds et al., 2006; Zhang et al., 2005).
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Peroxynitrite has also been shown to modify tau in-vivo. Injection of the PN donor, SIN-1,
into rat hippocampus results in both nitration and hyperphosphorylation of tau, and
increased activation of the tau kinases, GSK-3β and p38 MAPK, processes are attenuated by
pre-administration of the PN scavenger, uric acid (Zhang et al., 2006). SIN-1 administration
increased levels of nitrated p85, a regulator of GSK-3β, suggesting that PN is capable of
inducing tau hyperphosphorylation by nitration of upstream proteins in tau phosphorylation
cascade (Zhang et al., 2006). Furthermore, SIN-1 also led to a decrease in proteasome
activity, which combined with the fact that the nitrated form of tau is less susceptible to
proteasomal degradation, resulted in an increase in tau aggregation (Zhang et al., 2006).
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In summary, there are several mechanisms by which the reactive species, PN, can induce tau
pathology, including oxidation, nitration, and induction of tau hyperphosphorylation,
processes which lead to accumulation of toxic tau aggregates and/or destabilization of
microtubules. PN is generated following TBI; therefore it is possible that the PN formed
acutely following TBI initiates tau dysfunction, while other mechanisms of PN generation,
such as continued mitochondrial dysfunction, contribute to chronic PN-induced tau
dysfunction as suggested in Figure 3.
4.3 Lipid Peroxidation-Derived Neurotoxic Aldehydes
Lipid peroxidation-derived aldehydes have been found to be elevated in the brains of several
tauopathies (Butterfield et al., 2010; Lovell et al., 2001; Markesbery and Lovell, 1998;
Martinez et al., 2008a; Martinez et al., 2008b; Montine et al., 1997; Muntane et al., 2006;
Odetti et al., 2000; Sayre et al., 1997). In fact, in PSP, a tauopathy with paired helical
filament morphology distinct from AD, significant increases in 4-HNE are correlated with
tau aggregation, suggesting that accumulation of 4-HNE may contribute to impairment of
tau degradation (Odetti et al., 2000).
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The LP-derived aldehydes 4-HNE and acrolein are both capable of inducing tau pathology.
In-vitro, administration of 4-HNE to cultured rat hippocampal neurons results in direct
binding of 4-HNE to tau, preventing dephosphorylation of tau by alkaline phosphatases
(Mattson et al., 1997). Acrolein, a more potent neurotoxic aldehyde than HNE (Vaishnav et
al., 2010), also induces hyperphosphorylation of tau, both in neuroblastoma cells and in
cultured cortical mouse neurons, an effect which can be attenuated by inhibiting the tau
kinases, GSK-3β and p38 MAPK (Gomez-Ramos et al., 2003).
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In addition to inducing tau hyperphosphorylation, 4-HNE and acrolein are also capable of
promoting tau aggregation. In P19 neuroglial cultures, 4-HNE addition results in
cytotoxicity and formation of high molecular weight tau species characteristic of
neurofibrillary tangles (Montine et al., 1996). However, the effect of 4-HNE on tau
aggregation is greatest for tau which has already been hyperphosphorylated. In-vitro,
administration of 4-HNE promotes assembly of phosphorylated tau, but not native tau, into
neurofibrillary tangle-like fibrillary polymers (Perez et al., 2000). Phosphorylation of tau is
also required in order for 4-HNE to induce conformational changes to tau, such as the Alz50
epitope conformational change characteristic of early AD (Liu et al., 2005; Takeda et al.,
2000). Therefore, 4-HNE may play a role in NFT formation by stabilizing pathologic tau
confirmations (Liu et al., 2005). However, 4-HNE does not further enhance aldehydic
modification of paired helical filaments, suggesting that paired helical filaments are either
already extensively modified by aldehydes or that they are in a confirmation which prevents
further aldehyde modifications (Liu et al., 2005). Acrolein also promotes tau aggregation in
a concentration-dependent manner, with the fastest aggregation rates occurring in
pseudophosphorylated tau, further suggesting that hyperphosphorylation of tau increases its
susceptibility to aldehyde-induced aggregation (Kuhla et al., 2007).
While LP-derived aldehydes have a demonstrated ability to induce tau pathology, tau itself
can enhance formation of LP-derived aldehydes. For example, in brain homogenates derived
from transgenic mice overexpressing mutant human tau, P301L, ferric iron-induced LP
results in increased formation of the LP-derived aldehyde, malondialdehyde, compared to
wild-type mice (David et al., 2005).
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In summary, LP-derived aldehydes are known to be present in human tauopathies, and LPderived aldehydes, such as 4-HNE and acrolein, are capable of inducing tau phosphorylation
and promoting and stabilizing tau aggregation, in particular the aggregation of
hyperphosphorylated tau. Therefore, it is possible that following TBI, increases in 4-HNE
and acrolein and increases in hyperphosphorylated tau work synergistically to promote tau
aggregation, while other mechanisms of 4-HNE and acrolein generation, such as continued
mitochondrial dysfunction and tau-induced LP, contribute to a chronic, self-promoting and
cyclic cascade of LP and pathologic tau formation (Figure 4).
4.4 Mitochondrial Dysfunction
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Alterations in mitochondrial function are known to occur in the tauopathies, AD and FTD
(Baloyannis, 2006; David et al., 2005), and in normal aging (Swerdlow, 2011). Several
studies indicate that mitochondrial dysfunction is capable of inducing tau dysfunction, and
that tau itself is capable of inducing mitochondrial dysfunction.
Impairment of oxidative phosphorylation can lead to tau dysfunction and pathologic tau
formation both in-vitro and in-vivo. For example, in primary rat striatal rat neurons,
inhibition of complex-I, inhibition of complex-II, or uncoupling of oxidative
phosphorylation leads to decreased ATP production, cellular death and retrograde transport
of tau and mitochondria from the axons to the soma (Escobar-Khondiker et al., 2007). In
fact, complex-I inhibited neurons contain somal mitochondria which associate with tau at
the outer mitochondrial membrane (Escobar-Khondiker et al., 2007). In-vivo, inhibition of
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complex-I can also induce tau pathology. Chronically infusing the complex-I inhibitor,
rotenone, into rats results in cell death, motor dysfunction, and increases in cytosolic tau,
phosphorylated tau, and neuronal, glial, and oligodendrocytic tau fibrils (Hoglinger et al.,
2005). Furthermore, increased levels of the PN marker, 3-NT, and ubiquitin, a marker for
defective protein degradation, are found within cells containing pathologic tau (Hoglinger et
al., 2005). Mitochondrial dysfunction is known to lead to PN formation (Bringold et al.,
2000; Radi et al., 2002) and can indirectly reduce proteosomal activity (Hoglinger et al.,
2005). Therefore, it is possible that complex-I induced mitochondrial dysfunction can lead
to formation of pathologic tau through a combination of mechanisms including
mitochondrial and tau redistribution, generation of reactive nitrogen species, and impairment
of proteosomal degradation pathways.
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Pathologic tau has also been observed in transgenic mice lacking the mitochondrial
antioxidant enzyme SOD2. Mitochondrial SOD2 catalyzes the dismutation of superoxide
(O2•-), formed when single electrons leak from complex I of the electron transport chain
(Brand et al., 2004), to the less reactive oxygen species, H2O2 (Flynn and Melov, 2013).
Thus, SOD2 is an essential enzyme without which the undismutated O2•- wil react with
mitochondrial NO• to form the reactive nitrogen species PN. . However, pharmacological
administration of the catalytic antioxidant EUK-189 is able to attenuate tau phosphorylation
in SOD2 deficient mice (Melov et al., 2007), confirming that mitochondrial generated O2•or downstream PN (formed upon reaction of mitochondrial O2•- and NO•) is capable of
driving tau phosphorylation (Melov et al., 2007). Additional evidence supports the theory
that mitochondrial dysfunction can induce tau phosphorylation. In transgenic mice
overexpressing the human tau mutation, P301S, mitochondrial abnormalities, including
carbonyl modification of mitochondrial proteins and decreases in mitochondrial enzyme
activities, precede tau hyperphosphorylation and tangle formation by at least three months
(Dumont et al., 2011). However, while it is likely that the mitochondrial abnormalities
contributed to pathologic tau development, it is also likely that the overexpression of
mutated human tau itself induces mitochondrial abnormalities.
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Multiple studies provide evidence that tau can induce mitochondrial dysfunction.
Mitochondria are synthesized in neuronal cell bodies and then transported throughout the
neuron along microtubules by the anterograde motor protein, kinesin (Chang et al., 2006;
Morris and Hollenbeck, 1995), while damaged mitochondria are transported toward the
soma by the retrograde motor protein, dynein (Miller and Sheetz, 2004). Therefore, neuronal
health relies extensively on proper axonal transport of mitochondria. In CTE, fast axonal
transport along microtubules is impaired, with decreases being seen both in kinesin and
dynein (Kokjohn et al., 2013). Tau is primarily found in axons, functioning to stabilize
microtubules (Maccioni and Cambiazo, 1995); however, tau also serves to regulate the
attachment and detachment of motor proteins (Trinczek et al., 1999). Therefore, it has been
hypothesized that overexpression of tau or accumulation of pathologic tau can impair axonal
transport of mitochondria to the synapse, resulting in decreased synaptic ATP, calcium
dysregulation and neurodegeneration (Sheng and Cai, 2012). However, it should be noted
that in addition to mitochondria, tau-induced impairment of axonal transport affects
additional organelles, vesicles, and proteins, and that each likely contributes to their own
downstream pathologies. For example, tau overexpression can inhibit trafficking of
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peroxisomes, neurofilaments, Golgi-derived vesicles, the ER, and amyloid precursor protein
(APP) (Darios et al., 2005; Ebneth et al., 1998; Stamer et al., 2002), the precursor to Aβ, a
pathologic species found in the tauopathy AD and in a subset CTE cases.
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In regard specifically to axonal transport of mitochondria, several mechanisms by which tauinduced impairment of axonal transport have been reported. In-vitro, overexpression of tau
in neuroblastoma cells leads to preferential impairment of anterograde mitochondrial
transport, resulting in mitochondria that are clustered near nuclei but absent in neurites
(Ebneth et al., 1998). The degree to which tau overexpression interferes with mitochondrial
transport is influenced by the number of microtubule binding domain repeats. For instance,
overexpression of either 3R or 4R tau leads to redistribution of mitochondria from axons to
the soma (Stoothoff et al., 2009); however, 4R tau, the isoform expressed to a greater degree
in AD and CTE (McKee et al., 2014; Schmidt et al., 2001) has the greatest effect on
redistribution (Stoothoff et al., 2009). The N-terminus of tau has also been shown to be
sufficient for inhibiting anterograde transport (LaPointe et al., 2009). In fact, filamentous
tau, which contains an exposed N-terminus, inhibits kinesin-dependent fast axonal transport,
whereas monomeric tau confirmations with unexposed N-terminal regions do not (LaPointe
et al., 2009). Hyperphosphorylation of tau at AD-specific sites also results in decreased
mitochondrial transport due to extension of the N-terminal projection domain and expansion
of inter-microtubule distances (Shahpasand et al., 2012). Additional studies confirm the
ability of phosphorylated tau impair anterograde transport. Inhibition of anterograde
transport by filamentous tau is dependent upon on activation of the tau kinase, GSK-3β
(LaPointe et al., 2009). In PC12 cells, ceramide-induced CDK5-dependent tau
phosphorylation results in dissociation of phosphorylated tau from the microtubules,
clustering of mitochondria and ER near the centrosome, and cell death, effects which are
attenuated by preventing tau phosphorylation (Darios et al., 2005).
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Tau-induced impairment of mitochondrial transport likely has pathologic implications
beyond decreased delivery of mitochondria to the synapse. For example, the clustering of
mitochondria and ER near the centrosome in PC12 cells results in an increase in
mitochondria-ER associations, neurotoxic transfer of Ca2+ from the ER to the mitochondria,
and induction of apoptosis (Darios et al., 2005). Pathologic mitochondria-ER associations
have also been observed in the soma of spinal motor neurons in transgenic mice
overexpressing the human tau mutation, P301L (Perreault et al., 2009), and correlate with
accumulation of hyperphosphorylated tau at the surface of the rough ER (rER) (Perreault et
al., 2009). In fact, hyperphosphorylated tau is found on the surface of rER in the tauopathy,
AD (Perreault et al., 2009). Because mitochondria-ER associations require the ER to be
absent ribosomes, it is possible that tau is capable of inducing mitochondria-ER associations
by displacing ribosomes from the ER surface (Perreault et al., 2009).
In addition to impairment of mitochondrial transport and alterations in mitochondrial-ER
dynamics, other tau-induced mitochondrial impairments have been reported such as
abnormal morphology. For example, neurons from transgenic mice overexpressing the
human tau mutation, P301L, have decreased numbers of mitochondria and mitochondria
which have abnormally swollen morphology (Yoshiyama et al., 2007).
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Tau-induced decreases in oxidative phosphorylation capacity have also been reported. The
mitochondria from P301L mice have reductions in complex I (David et al., 2005; Rhein et
al., 2009) and complex V (ATP synthase) protein and activity levels (David et al., 2005).
Additionally, aged P301L mice have decreases in ATP production and increases in ROS due
to decreases in complex-I driven respiration (David et al., 2005). Importantly, reductions in
complex V (ATP synthase) have also been seen in the human tauopathy, FTD (David et al.,
2005).
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Although many studies that investigate the effect of tau on mitochondrial function rely on
mutated forms of human tau, the mutant tau constructs, such as P301, do induce tau
hyperphosphorylation. Therefore, the mutant tau constructs are representative of nongenetic, hyperphosphorylated tau disease states. However, the possibility exists that mutated
tau isoforms cause greater mitochondrial dysfunction than wild type tau. For example, stable
overexpression of human mutant tau, P301L, into SY5Y cells results in complex I
impairment, decreased ATP production, increased susceptibility to oxidative stress,
abnormal morphology, and fission-fusion dysfunction (Schulz et al., 2012); however,
overexpression of wild-type 4R human tau results in increases in complex I activity, normal
morphology and normal fission-fusion dynamics (Schulz et al., 2012).
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Tau oligomers, which have been implicated as the species responsible for tau-induced
neurotoxicity (Spires-Jones et al., 2011), are also capable of inducing mitochondrial
dysfunction. Injections of full-length human tau oligomers, but not tau fibrils or monomers,
into mouse hippocampi induce memory impairment, neurodegeneration, loss of synaptic
proteins, and mitochondrial dysfunction (Lasagna-Reeves et al., 2011). Specifically, the tau
oligomers co-localized with mitochondria, decreasing complex I protein levels, and
activating the intrinsic apoptotic protease, caspase-9 (Lasagna-Reeves et al., 2011).
However, complex V protein levels were not altered, suggesting that complex I dysfunction
occurs prior to tau-induced complex V dysfunction and ATP depletion (Lasagna-Reeves et
al., 2011).
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Truncated tau fragments are also capable of inducing mitochondrial dysfunction. In
immortalized cortical neurons, Asp421 tau, a mutant mimicking C-terminus caspase-3
cleavage of tau at Asp421, induces mitochondrial fragmentation, decreases mitochondrial
calcium buffering capacity, and increases production of mitochondrial ROS (Quintanilla et
al., 2009), effects which are attenuated by administration of the calcineurin inhibitors
cyclosporine A (CsA) or FK506, suggesting that the calcium-dependent phosphatase,
calcineurin, plays a role in caspase-cleaved tau induction of mitochondrial dysfunction
(Quintanilla et al., 2009). Tau is a known calcineurin substrate; therefore, it is possible that
caspase-cleaved tau interacts differentially with calcineurin, increasing its activity level
toward substrates which effect mitochondrial fragmentation (Quintanilla et al., 2009).
Interestingly, both CsA and FK506 are neuroprotective in experimental TBI (Kilbaugh et al.,
2011; Kulbe et al., 2016; Marmarou and Povlishock, 2006; Mbye et al., 2009; Mbye et al.,
2008; Reeves et al., 2007; Sullivan et al., 2011), and CsA has been shown to attenuate levels
of cleaved tau in the hippocampus of rats following severe controlled cortical impact injury
(CCI) (Gabbita et al., 2005).
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In addition to C-terminal cleavage, truncated tau fragments can also be generated by Nterminal processing. Although this process is not well understood, caspases, such as
caspase-6 have the ability to cleave tau at the N-terminus (Horowitz et al., 2004), and Nterminal tau fragments have been reported to induce mitochondrial dysfunction. For
example, addition of the NH2-26-44 tau fragment to cerebellar granule neuron homogenates
results in decreases in cytochrome oxidase (COX) activity, adenine nucleotide translocator
(ANT) activity, and ANT-dependent impairment of oxidative phosphorylation (Atlante et al.,
2008). Importantly, N-terminal tau fragments have been identified in AD and other
tauopathies (Amadoro et al., 2010). In fact, in AD, a 20-22kD NH2-tau fragment is highly
enriched in synaptosomes, localizing with synaptic mitochondria, and correlating with
synaptic and mitochondrial dysfunction (Amadoro et al., 2010). Synapses have high
metabolic demands, met by enrichment of synaptic mitochondria (Khatri and Man, 2013;
MacAskill et al., 2010). Not only are synaptic mitochondria essential for proper
neurotransmission (Sheng and Cai, 2012) and synaptic plasticity (Cheng et al., 2010;
MacAskill et al., 2010; Sheng and Cai, 2012), but their dysfunction is implicated in
neurodegeneration (Cheng et al., 2010; Sheng and Cai, 2012). Therefore, localization of the
20-22kD NH2-tau with synaptic mitochondria has important implications for synaptic
health, especially considering the fact that 20-22kD NH2-tau is capable of inducing
mitochondrial dysfunction. In vitro, the 20-22kD NH2-tau fragment induces abnormal
mitochondrial morphology, increases mitochondrial fragmentation, decreases mitochondrial
fusion, enhances redistribution of mitochondria to the soma, decreases mitochondrial protein
and mtDNA copy number, and enhances mitophagy, effects which correlate with in-vitro
synaptic pathology and oxidative stress (Amadoro et al., 2014).
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In addition to truncated tau species, phosphorylated tau has also been implicated in
alteration of mitochondrial fission-fusion dynamics. Specifically, in the tauopathy AD,
phosphorylated tau interacts with Drp1, a mitochondrial fission GTPase, and is associated
with increases in GTPase activity indicative of mitochondrial fission, suggesting that
phosphorylated tau may enhance mitochondrial fragmentation through interaction with Drp1
(Manczak and Reddy, 2012).
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In summary, mitochondrial dysfunction is known to occur in human tauopathies, and there
are several mechanisms by which mitochondrial dysfunction can induce tau pathology and
by which pathologic tau species can induce mitochondrial dysfunction. Therefore, a primary
event capable of inducing mitochondrial dysfunction or formation of pathologic tau species,
such as TBI, could set off a self-propagating, cyclical cascade of mitochondrial dysfunction
and pathologic tau formation, which work synergistically to induce cellular damage. In fact,
in transgenic mice expressing mutations which induce both mitochondrial dysfunction and
tau pathology, neurodegeneration and oxidative stress are increased over either mutation
alone (Kulic et al., 2011). Furthermore, in addition to a self-propagating, cyclical cascade of
mitochondrial-tau dysfunction, because mitochondrial impairment results in production of
species capable of inducing damage to mitochondrial DNA (mtDNA), which encodes for
electron transport chain proteins (Dalleau et al., 2013; Hall et al., 2010), mitochondrial
dysfunction is capable of enhancing and perpetuating its own chronic damage. In fact,
accumulations in mtDNA damage have been hypothesized to contribute to both aging and
neurodegenerative disease (Keogh and Chinnery, 2015).
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ER stress has been documented in several tauopathies, including AD, FTD, and CTE, and
correlates with tau hyperphosphorylation (Hoozemans and Scheper, 2012; Hoozemans et al.,
2009; Lucke-Wold et al., 2016; Nijholt et al., 2012). ER dysfunction has been reported to
occur both upstream and downstream of pathologic tau formation (Ho et al., 2012).
Upstream of tau, pharmacological induction of ER stress increases tau phosphorylation both
in-vitro and in-vivo (Fu et al., 2010; Ho et al., 2012; Lin et al., 2014). One mechanism by
which ER stress can increase tau phosphorylation is through activation of the tau kinase,
GSK-3β (Fu et al., 2010; Lin et al., 2014). However, pathologic tau species can also induce
ER dysfunction. The ER is responsible for protein folding and degradation; therefore, ER
stress results in the build-up of misfolded and unfolded proteins, inhibition of ER-associated
degradation (ERAD), initiation of the Unfolded Protein Response (UPR), and decreased
protein synthesis (Abisambra et al., 2013; Radford et al., 2015).
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Tau is capable of activating the UPR in-vitro. Pharmacologic induction of tau
phosphorylation in primary rat cortical neurons results in UPR activation (Ho et al., 2012).
Similarly, stable expression of tau in HEK cells activates the UPR and is accompanied by
increased ubiquitin levels suggestive of ERAD impairment (Abisambra et al., 2013). In-vivo,
the UPR is known to be increased in both transgenic tau animal models and human
tauopathies (Abisambra et al., 2013; Hoozemans and Scheper, 2012; Hoozemans et al.,
2009; Nijholt et al., 2012; Radford et al., 2015). It has been hypothesized that the increased
UPR seen in tauopathies is the result of tau-induced ERAD impairment (Abisambra et al.,
2013). For example, transgenic mice overexpressing human mutant tau, P301L, show ERAD
impairment concomitant with associations between tau and the ERAD hetereocomplex
(Abisambra et al., 2013). However, activation of UPR in tauopathies may also be due to the
buildup of misfolded tau proteins (Radford et al., 2015). UPR activation has also been
suggested to play a direct role in neurotoxicity. In fact, pharmacologic inhibition of the UPR
in P301L mice decreases tau phosphorylation, neurodegeneration, and behavioral
impairment (Radford et al., 2015).
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An additional mechanism by which tau induced ER dysfunction can contribute to cellular
dysfunction is inhibition of protein synthesis. Microsomes are vesicle-like fragments which
contain ER and ribsosomes. In brain microsomes isolated from the tauopathy, AD,
oligomeric tau associates more strongly with ribosomes than in control brains, suggesting
that pathologic tau may have an effect on RNA translation (Meier et al., 2016). In fact, invitro, wild type, mutant, and oligomeric tau are all able to reduce RNA translation (Meier et
al., 2016), and in primary neurons cultured from transgenic mice overexpressing human
mutant tau, P301L, there are both decreases in RNA translation and protein levels (Meier et
al., 2016). Specifically, there are marked decreases in the protein PSD-95, a post-synaptic
protein important in learning and memory (Meier et al., 2016).
Soluble tau oligomers and truncated tau forms have been specifically implicated in tau
induced ER dysfunction. Depleting soluble tau both in cell culture and in P301L mice
reduces UPR activation and inhibition of ERAD, suggesting soluble tau oligomers rather
than insoluble tau aggregates are responsible for tau-induced ER dysfunction (Abisambra et
al., 2013). In regards to truncated tau isoforms, inducing ER stress in immortalized cortical
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neurons expressing Asp-421 truncated tau, which mimics caspase-3 cleavage, results in
increased cellular toxicity and caspase-3 activation compared to cells expressing full length
tau (Matthews-Roberson et al., 2008). In fact, ER stress itself has the capability of inducing
the caspase-3 activation (Morishima et al., 2002; Song et al., 2002) which leads to tau
truncation.
In summary, ER stress is known to occur in several tauopathies, including CTE, and there
are several mechanisms by which ER stress can induce tau pathology and by which
pathologic tau species can induce ER dysfunction. Therefore, as summarized in Figure 5, a
primary event capable inducing ER stress or tau pathology, such as TBI, could set off a
chronic and self-propagating cascade of ER dysfunction and pathologic tau formation,
which results in protein accumulation, decreased protein synthesis, and cellular dysfunction.

Author Manuscript

4.6 Calpain Activated Proteolysis
Tau is a known substrate of the calcium-dependent cysteine protease, calpain (Johnson et al.,
1989; Litersky et al., 1993; Yang and Ksiezak-Reding, 1995). Calpain cleavage of tau results
in the formation of a 35kD tau fragment (Liu et al., 2011) and a 17kD tau fragment,
purported to be between 10-17kD (Garg et al., 2011; Park and Ferreira, 2005). Increased
calpain activity and depletion of the endogenous calpain inhibitor, calpastatin, have been
found in the tauopathy, AD, (Grynspan et al., 1997; Rao et al., 2008; Saito et al., 1993; Tsuji
et al., 1998) and the presence of the 17kD tau fragment correlates with increases in calpain
activity in a variety of tauophathies, including AD, FTD and dementia pugilistic (i.e. CTE)
(Ferreira and Bigio, 2011).
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The 17kD tau fragment has a decreased association with the microtubules and accumulates
in the perikarya (Canu et al., 1998). In-vitro, glutamate and thapsigargin induced increases
in calcium have been shown to induce formation of calpain-cleaved 17kD tau (Garg et al.,
2011). The 17kD tau fragment has been reported for form prior to increases in tau
phosphorylation (Park and Ferreira, 2005), and is suspected of being neurotoxic (Park and
Ferreira, 2005; Park et al., 2007; Sinjoanu et al., 2008). For example, in-vitro, Aβ induces
calpain activation in cultured hippocampal neurons, leading to formation of 17kD tau and
neurodegeneration, affects which are attenuated by inhibiting calpain activation (Park and
Ferreira, 2005; Park et al., 2007; Sinjoanu et al., 2008). However, other studies have shown
that 17kD tau does not induce toxicity in-vitro and is equally expressed in the brains of AD
and healthy controls, suggesting that 17kD tau is a marker for calpain activation but does not
have a direct role in neurotoxicity (Garg et al., 2011).
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In addition to cleaving tau, calpain has also been identified as an upstream activator of
extracellular-regulated kinase (ERK) (Veeranna et al., 2004), which is capable of
phosphorylating tau (Fang et al., 2010; Qi et al., 2016), In fact, increases in active ERK
expression are associated with early tau deposition in neurons and glia in several tauopathies
(Ferrer et al., 2001).
Despite controversy surrounding the role of the calpain generated 17kD tau fragment in
neurotoxicity, both increases in calpain and 17kD tau have been identified in human
tauopathies. Due to increases in intracellular calcium levels, calpain is highly activated
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following TBI (Deng et al., 2007; Thompson et al., 2006); therefore it is possible that TBI
initiates formation of calpain-cleaved 17kD tau, whereas chronic generation of 17kD tau
could be the result of calpain activation by calcium derived from chronically dysfunctional
calcium buffering organelles suspected of having self-propagating, cyclic interactions with
pathologic tau, such as the mitochondria and ER (Figure 6).
4.7 Caspase Activated Proteolysis
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Tau is a known substrate of the caspase proteases (Fasulo et al., 2000; Park et al., 2007),
which are well known for their role in apoptosis. The most well characterized caspase
cleavage site on tau is Asp421, located on the c-terminus end. Multiple caspases, including
caspase 3, can cleave tau at Asp421 (Gamblin et al., 2003), which results in a tau fragment
of 50kD (Chung et al., 2001; Park et al., 2007). However, tau can also undergo n-terminal
processing by caspases, such as caspase-6 (Horowitz et al., 2004). Caspase cleaved tau is
found in several tauopathies (Guillozet-Bongaarts et al., 2007; Newman et al., 2005), and is
inversely correlated with cognitive function in the tauopathy, AD (Rissman et al., 2004),
with formation of Asp421 truncated tau considered to occur relatively early in the disease
process (Guillozet-Bongaarts et al., 2005; Rissman et al., 2004). It is hypothesized that
accumulation of Asp421 truncated is the result of dysregulation of autophagy, a process
known to occur in the tauopathy, AD (Nixon, 2006). In fact, in immortalized cortical
neurons, stably expressed Asp421 truncated tau is preferentially degraded by autophagy,
while full length tau is dependent on proteasomal degradation (Dolan and Johnson, 2010).
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Several lines of evidence suggest that Asp421 truncated tau is pathologic. In-vitro, the cterminus of tau is responsible for inhibiting polymerization of tau, suggesting that Asp421
truncated tau has enhanced polymerization properties (Berry et al., 2003). In fact, Asp421
truncated tau assembles into filaments at a faster rate and to a higher degree than full length
tau (Gamblin et al., 2003; Rissman et al., 2004). Furthermore, full length tau undergoes
enhanced filament formation in the presence of Asp421 truncated tau, suggesting that
Asp421 truncated tau may be able to seed filament formation of other tau species (Rissman
et al., 2004). In-vitro, overexpression of Asp421 truncated tau, representative of caspase-3
cleaved tau, results in increased apoptosis (Chung et al., 2001; Fasulo et al., 2000).
Caspase-3 is an executioner caspase in the apoptotic cascade; therefore, the fact that
caspase-3 cleaved tau is capable of enhancing apoptosis suggests that caspase-3 and Asp421
truncated tau may be involved in a chronic, self-propagating apoptotic cascade (Fasulo et al.,
2000). Additionally, as previously discussed, caspase cleaved tau fragments are also capable
of inducing mitochondrial dysfunction (Quintanilla et al., 2009) and ER stress (MatthewsRoberson et al., 2008).
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Evidence suggests that non-truncated tau forms can also initiate caspase activation and tau
truncation. For example, overexpressing human mutant tau P301L in mice results in
apoptosis, caspase-3 activation, and appearance of caspase truncated tau (de Calignon et al.,
2010; Ramalho et al., 2008). Similarly, overexpression of human 4R tau results in caspase
activation, although total numbers of caspase bearing neurons are low (de Calignon et al.,
2010). Therefore, it is possible that, in-vivo, full-length pathologic tau, particularly soluble
pre-tangle tau species, are capable of activating caspase-3, which results in formation of
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distinct truncated tau species. In fact, suppression of tau in P301L mice decreases caspase
activation despite the continued presence of neurofibrillary tangles (de Calignon et al.,
2010).
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Although formation of caspase truncated tau is considered to occur early in the disease
process (Guillozet-Bongaarts et al., 2005; Rissman et al., 2004), Asp421 truncated tau is still
capable of inducing tau phosphorylation and conformational change (de Calignon et al.,
2010) and can be the subject of phosphorylation and conformation change itself (Rissman et
al., 2004). However, similar to human studies, transgenic animal models of tauopathy
suggest that formation of caspase truncated tau occurs prior to tau aggregation and correlates
with cognitive decline. In fact, in P301L mice, caspase cleavage of tau proceeds
neurofibrillary tangle formation (de Calignon et al., 2010; Ramalho et al., 2008), and is
coincident with the beginnings of cognitive impairment (Ramalho et al., 2008). Furthermore,
animal models confirm in-vitro findings that caspase truncated tau can seed filament
formation of full length tau (Gamblin et al., 2003; Rissman et al., 2004). For example,
virally overexpressing Asp421 tau in wild type mice results in formation of tau aggregates
which contain both Asp421 truncated and full length tau (de Calignon et al., 2010).
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As illustrated in Figure 7, tau is a substrate for the apoptotic caspase proteases and caspase
truncated tau is present in human tauopathies. Additionally, caspase cleaved can induce
cellular dysfunction. Apoptosis and caspase activation occurs following TBI; therefore, it is
possible that TBI-induced caspase activation can initiate formation of caspase cleaved tau,
whereas long-term generation of caspase truncated tau could be the result of chronic caspase
activation due to chronic mitochondrial dysfunction or ER stress, organelles suspected of
having self-propagating, cyclic interactions with pathologic tau. In fact, in P301L mice,
activated executioner caspases can be found in neurons containing late stage neurofibrillary
tangles, despite the absence of apoptosis (Spires-Jones et al., 2008). Furthermore, because
caspase truncated tau is capable of activating caspase-3, impairing mitochondrial function,
and enhancing ER stress, it is possible that caspase truncated tau itself can self-propagate its
formation.
4.8 Neuroinflammation

Author Manuscript

Neuroinflammation occurs in multiple tauopathies including CTE, AD, PSP, Pick's disease,
and corticobasal degeneration (Daneshvar et al., 2015; Ishizawa and Dickson, 2001; Sasaki
et al., 2008; Zilka et al., 2009a). Astrocytes and microglia make up two of the most
important cells of the CNS innate immune system. Astrocytes containing pathologic tau
have been identified in several tauopathies, including CTE (Kahlson and Colodner, 2015;
McKee et al., 2016). Similarly, microglia are activated in CTE and other tauopathies (Cherry
et al., 2016; Faden and Loane, 2015; Ishizawa and Dickson, 2001; Saing et al., 2012; Sasaki
et al., 2008; Zilka et al., 2009a). Evidence suggests that neuroinflammation can both induce
tau pathology and be induced by pathologic tau species.
Under physiologic conditions astrocytes contain limited amounts of tau protein, and tau is
not considered to be a major component of the astrocyte cytoskeleton (Kahlson and
Colodner, 2015). However, in CTE and other tauopathies, hyperphosphorylated tau is
present in astrocytes (Kahlson and Colodner, 2015; McKee et al., 2016). Although astrocytic
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tau pathology is not well defined in CTE, supporting neuropathological criteria for the
diagnosis of CTE includes p-tau positive thorned astrocytes located at the glial limitans in
the subpial and periventricular regions (McKee et al., 2016). Additionally, the astrocytic tau
of CTE is known to be composed mainly of the 4R subtype (McKee and Robinson, 2014).
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Although the phenotypes of the astrocytes containing hyperphosphorylated tau vary between
tauopathies, thorned astrocytes, such as those characteristic of CTE, morphologically
resemble reactive astrocytes and therefore may be indicative of a neuroinflammatory
response similar to gliosis (Kahlson and Colodner, 2015), a process known to occur
following TBI (Burda et al., 2016). The presence of hyperphosphorylated tau within
astrocytes is hypothesized to have several consequences for astrocytic function (Kahlson and
Colodner, 2015). Astrocytes assist in maintenance of the blood-brain barrier; therefore, it is
possible that astrocytic tau pathology can lead to blood-brain barrier dysfunction (Kahlson
and Colodner, 2015). For example, overexpressing human tau in the astrocytes of mice
results in mild blood-brain barrier disruption in areas of extensive astrocytic tau pathology
(Forman et al., 2005). In addition to maintenance of the blood-brain barrier, astrocytes
remove excessive extracellular glutamate; therefore, it is possible that astrocytic tau
pathology can lead to impairment of extracellular glutamate removal, resulting in neuronal
excitotoxicity and synaptic dysfunction (Kahlson and Colodner, 2015). In fact,
overexpressing either human wild-type or mutant P301L tau in the astrocytes of mice results
in a decrease in astrocyte glutamate transporter expression and activity which correlates with
behavioral impairment (Dabir et al., 2006). Furthermore, overexpressing tau in astrocytes
leads to astrocyte degeneration both in-vitro and in-vivo (Higuchi et al., 2002; Yoshiyama et
al., 2003), and overexpressing human tau in the astrocytes of mice results in neuronal
degeneration in regions associated with astrocytic tau pathology (Forman et al., 2005),
indicating astrocytic tau pathology may play a direct role in both astrocytic and neuronal cell
death (Kahlson and Colodner, 2015).
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Although several tauopathies contain astrocytic tau pathology, evidence suggests that
astrocytes do not phagocytise pathologic tau species. In the tauopathies, AD and FTD, tau
oligomers are found to be surrounded by active astrocytes, but are not co-localized with
astrocytes, suggesting the occurrence of an inflammatory response, but that astrocytes do not
internalize tau oligomers (Nilson et al., 2016). Conversely, in AD, FTD, and transgenic mice
overexpressing human tau (hTau), tau oligomers are found co-localized with active
microglia, suggesting active phagocytosis of tau oligomers by microglia (Nilson et al.,
2016). In fact, microglia themselves have been implicated in the anatomic spread of tau
pathology (Nilson et al., 2016). As shown in Figure 8, microglia are capable of both
phagocytosis and exocytosis; therefore, microglial-dependent propagation of tau through
phagocytosis and exocytosis may explain non-synaptic spread of tau throughout the brain
(Asai et al., 2015). The depletion of microglia has been shown to reduce the propagation of
tau in-vivo, both in an adenovirus model of rapid tau propagation and in transgenic mice
overexpressing human mutant tau, P301S (Asai et al., 2015). Furthermore, transplanting
microglia obtained from the brains of transgenic mice overexpressing human tau (hTau) and
null for the microglial receptor, CX3R1, to the brains of wild-type mice results in increases
in phosphorylated tau within the wild-type brains (Maphis et al., 2015b).
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The neuronal-microglial chemokine-chemokine receptor signaling pathway, CX3CL1CX3CR1 has been implicated in both neurodegeneration and neuroprotection following
CNS injury (Bhaskar et al., 2010). CX3CL1-CX3CR1 signaling is known to be altered
following TBI (Poniatowski et al., 2016), and may play a role in the development of tau
pathology. In fact, tau overexpression is capable of increasing CX3CL1 levels, whereas
CXCR1 depletion is capable of enhancing microglial activation and tau pathology.
Transgenic mice overexpressing human tau (hTau) show increased levels of the neuronallyderived ligand, CX3CL1 (Bhaskar et al., 2010). Knocking out the microglial receptor,
CXC3R1, in hTau mice results in increases in microglial activation which are correlated with
cognitive impairment (Bhaskar et al., 2010; Maphis et al., 2015b) In fact, hTau/CX3R1-/mice show earlier tau pathology than hTau/CX3R1+/+ mice (Maphis et al., 2015b).
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Alteration in the CX3CLI-CX3CR1 signaling pathway has been shown to enhance tau
phosphorylation upon systemic administration of lipopolysaccharide (LPS), a compound
capable of activating microglia through the TLR4 receptor (Bhaskar et al., 2010). LPSinduced activation of microglia increases tau phosphorylation in wild-type and hTau mice
(Bhaskar et al., 2010). However, the effect is enhanced in CX3R1-/- mice, further enhanced
in hTau/CX3R1-/- mice, and is dependent on neuronal activation of the tau kinase, p38
MAPK, and release of the microglial derived cytokine, IL-1β (Bhaskar et al., 2010).
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In hTau/CX3R1-/- mice, microglial activation occurs prior to the appearance of tau
pathology and correlates with its anatomic spread (Maphis et al., 2015b), suggesting that
microglia activation enhances formation of pathologic tau. Additionally, studies suggest that
microglial-induced neural toxicity is dependent on the presence of tau. Culturing neurons
with LPS-activated CX3R1-/- microglia results in increased neurodegeneration; however this
effect is attenuated in tau-/- neurons (Maphis et al., 2015a). Similarly, LPS activation of
microglia in CX3R1-/- mice results in caspase-3 activation which is localized to p-tau
positive neurons of the dentate gyrus, an effect which is attenuated in tau-/- mice (Maphis et
al., 2015a). In non LPS-stimulated CX3R1-/- mice, a reduction in microglial activation and
neuronal caspase-3 is also seen in tau-/- mice compared to tau+/+ mice (Maphis et al.,
2015a), an effect which correlates with attenuation of behavioral impairment (Maphis et al.,
2015a).
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In addition to the CX3CLI-CX3CR1 signaling studies, several additional lines of evidence
suggest that activation of microglia, as well as secretion of pro-inflammatory cytokines
contribute to tau pathology. In fact, in the tauopathy AD, microglial expression of IL-1β is
correlated with neuronal tau hyperphosphorylation (Sheng et al., 2001). In-vitro, activation
of microglia with LPS results in microglial secretion of IL-β, neuronal activation of the tau
kinase, p38 MAPK, increases in neuronal tau phosphorylation, and decreases in the synaptic
protein, synaptophysin (Li et al., 2003). In primary hippocampal neurons, the proinflammatory cytokine IL-6 has been shown to increase tau phosphorylation, an effect which
is attenuated by inhibiting the tau kinase, cdk5 (Quintanilla et al., 2004). Additionally,
exposing SY5Y or N-tera2 cells to media conditioned by LPS and IFNγ-activated human
microglia results in increased production and release of tau (Lee et al., 2015). In fact, direct
treatment of SY5Y or N-tera2 cells with the inflammatory cytokines, IL-1β or IL-6 was
sufficient to increase levels of tau mRNA and protein expression (Lee et al., 2015).
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In-vivo, systemic administration of the microglial activator, LPS, results in increased tau
phosphorylation acutely in the hippocampus of mice though activators of cdk5 and GSK-3β
activation (Roe et al., 2011). In regards to cytokine expression, implantation of IL-1β beads
into rat cerebral cortex, in simulation of chronic IL-1β exposure, results in increased mRNA
expression of tau and p38 MAPK and increased tau phosphorylation (Sheng et al., 2001;
Sheng et al., 2000). Similarly, adenovirus expression of the cytokine IFN-γ, a master
regulator of inflammation, in two different mouse models of P301L tau overexpression
results in increased phosphorylation of soluble tau through activation of the tau kinase,
GSK-3β, however, INF-γ induction of tau phosphorylation did not result in increased tangle
pathology or behavioral deficits (Li et al., 2015).
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Although activation of microglia has been shown to increase tau phosphorylation, the ability
of activated microglia to induce tau aggregation or tangle formation is less clear. For
example, in rTg4510 mice overexpressing human mutant tau P301L, injection of LPS
directly into the anterior cortex and hippocampus, results in ipsilateral and contralateral
microglia activation and increases in tau phosphorylation one week following injection;
however, pre-tangle and mature tangle formation was not increased (Lee et al., 2010).
Interestingly, in this model activated microglia also did not co-localize with p-tau positive
neurons (Lee et al., 2010). Conversely, in-vitro, activated microglia are capable of inducing
tau aggregation through a mechanism involving production of ROS and the cytokine, TNF.
Co-culturing primary hippocampal neurons with microglia pre-activated with LPS and IFNγ results in aggregation of tau in neurites as determined by FRET imaging, whereas tau
aggregation is not seen in neurons cultured in the absence of activated microglia (Gorlovoy
et al., 2009). Similarly, direct administration of the cytokine, TNF, to neuronal cultures
results in formation of tau aggregates and increases in neuronal ROS production (Gorlovoy
et al., 2009). In fact, TNF-induced tau aggregation is attenuated by the scavenging of ROS,
suggesting that microglial-induced tau aggregation may be due to microglial secretion of
TNF and activation of ROS generating neuronal NADPH oxidase (Gorlovoy et al., 2009).
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In addition to activated microglia being shown to induce tau pathology, tau has been shown
to activate microglia. In-vitro, transfection of microglia with Tau40, the longest isoform of
human tau, results in increases in microglia activation, migration, phagocytosis, and
cytokine secretion (Wang et al., 2013b). Additionally, in pure microglial cultures, Tau40
induces accumulation of endogenous phosphorylated tau at the cell membrane, enhances
secretion of non-phosphorylated tau, and alters expression of tau phosphatases and kinases
(Wang et al., 2013b). In-vivo, overexpression of human mutant tau, P301L, results in
increased expression of chemokines and innate immune system components (Li et al., 2015)
and activated microglia accumulate near p-tau positive neurons (Sasaki et al., 2008).
Similarly, in transgenic rats expressing truncated human tau, reactive microglia are
associated with neurofibrillary tangles and axonal degeneration (Zilka et al., 2009b).
Upon further examination, many of the transgenic tau animal models suggest a cyclic
relationship between microglial activation and formation of tau pathology. For example, the
overexpression of human mutant tau, P301S, in mice is sufficient to increase microglial
activation; however, microglial activation, synapse loss and impaired synaptic function all
precede filamentous tau formation (Yoshiyama et al., 2007).
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It is currently unclear whether neuroinflammation in CTE and other tauopathies is
detrimental or protective. In P301S mice, the immunosuppressant, FK506, is able to
attenuate neuroinflammation, neurodegeneration and tau pathology (Yoshiyama et al., 2007).
Similarly, minocycline, a tetracycline class antibiotic with neuroinflammatory properties, is
able to reduce astrocyte activation, the production of inflammatory cytokines, and decrease
tau phosphorylation in the cortex of transgenic mice overexpressing human tau (hTau)
(Garwood et al., 2010). Importantly, both FK506 and minocycline have been shown to be
neuroprotective in TBI (Miyauchi et al., 2013; Singleton et al., 2001; Vink and Nimmo,
2009).
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An additional pathway implicated in inflammation, the cholinergic pathway, is known to be
impaired in TBI and neurodegenerative disease. In TBI there are deficits in cholinergic
transmission and chronic loss of cholinergic neurons (Shin and Dixon, 2015), and recent
evidence has demonstrated the occurrence of tau pathology in the cholinergic neurons of the
nucleus basalis of Meynert in CTE brains (Mufson et al., 2016). The neurotransmitter,
acetylcholine (Ach), is purported to have anti-inflammatory properties and the cholinergic
pathway has been implicated in regulation of the immune system (Yoshiyama et al., 2012).
In fact, chronic administration of a centrally acting anti-cholinergic to mice overexpressing
human mutant tau, P301S, results in increases in tau phosphorylation and insolubility,
activation of tau kinases, neurodegeneration, and microglial activation (Yoshiyama et al.,
2012). Furthermore, anti-cholinergic administration enhances the effects of LPS-induced
microglial activation in P301S mice (Yoshiyama et al., 2012).
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Therefore, if neuroinflammation is a detrimental process, acetylcholine esterase inhibitors
(AChEI), which have long been used for symptomatic treatment of cognitive impairment in
neurodegenerative tauopathies but are also purported to have anti-inflammatory properties
due to their ability to upregulate cholinergic pathways (Yoshiyama et al., 2010), should be
neuroprotective in animal models of tauopathy. If fact, in transgenic mice overexpressing
human mutant tau, P301S, chronic treatment with the AChEI, donepezil, results in decreased
astrocyte and microglial activation, decreased tau phosphorylation and insolubility, and
decreased synaptic and neuronal loss (Yoshiyama et al., 2010). Furthermore, in P301S mice,
donepezil is able to attenuate LPS-induced microglial activation and reduce brain levels of
IL-1β and COX-2, suggesting that the neuroprotective effects of AChEI are due to
attenuation of neuroinflammation. (Yoshiyama et al., 2010).
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Although inhibition of neuroinflammation has been shown to be protective in some
tauopathy models, neuroinflammation may also serve a protective role against the
development of tau pathology and cognitive dysfunction through promotion of cellular and
debris clearance mechanisms. For example, in transgenic mice overexpressing human
mutant tau, P301S, LPS-induced activation of microglial also been shown to decrease
phosphorylated tau and improve cognitive function through the promotion of authophagy
(Qin et al., 2016).
Microglia themselves are also responsible for the clearance of damaged neurons, aberrant
synapses and demyelinated axons (Sanchez-Mejias et al., 2016). Therefore, degeneration of
microglia leads to neuronal degeneration in areas absent immune surveillance (Sanchez-
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Mejias et al., 2016). In the temporal cortex of the tauopathy, AD, dystrophic (degenerating,
fragmented, senescent, etc.) microglia are co-localized with degenerating neurons positive
for tau (Streit et al., 2009). Similarly, degenerating microglia are found in the hippocampus
of AD, a region in which phosphorylated tau preferentially accumulates over Aβ plaques
(Sanchez-Mejias et al., 2016). Although the appearance of dystrophic microglia, a
phenomenon known to increase with aging, precedes the spreading of tau pathology in AD,
suggesting that loss of microglial neuroprotection as one ages can lead to neurodegeneration
(Streit et al., 2009), additional evidence suggests that soluble phosphorylated tau is capable
of inducing microglial degeneration. For example, in-vitro, both phagocytosis of
extracellular soluble p-tau and phagocytosis of apoptotic SY5Y cells containing intracellular
soluble p-tau induces microglial toxicity, an effect which can be attenuated by immunodepletion of p-tau (Sanchez-Mejias et al., 2016).
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In summary, CTE and TBI share common neuroinflammatory processes such as astrogliosis
and activation of microglia. In fact, chronic neuroinflammation occurs in tauopathies and
TBI. In CTE, tau positive astrocytes have been hypothesized to have several detrimental
consequences, including blood-brain barrier dysfunction, extracellular glutamate
dysregulation, and induction of neurodegeneration. In addition to astrocytes, the activation
of microglia and the release of inflammatory cytokines have been implicated in induction of
tau pathology and neurodegeneration. However, pathologic tau, itself, is capable of inducing
both activation and degeneration of microglia, with degeneration of microglia capable of
inducing neurodegeneration. Therefore, it is possible that following an initial insult capable
of activating microglia and inducing pathologic tau formation, such as TBI, that microglia
and tau interact to induce a feedforward cycle of neuroinflammation, pathologic tau
formation, and neurodegeneration (Figure 8). In fact, chronic neuroinflammation is found
both in tauopathies and decades following TBI.

5. Tau - A Biomarker for TBI
Stretching, shearing and degeneration of axons following TBI causes tau to be released from
microtubules, increasing the levels of tau in biofluids. For this reason, there is growing
interest in using cerebral spinal fluid (CSF), plasma, or serum tau as a biomarker for TBI,
including mild TBI and sports-related head injury (Kulbe and Geddes, 2015). Furthermore,
CSF tau already holds diagnostic potential in the tauopathy, AD (Blennow et al., 2010).
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Increased levels of serum tau have been found in various models of animal TBI. For
example, on the severe end of the spectrum, the cleaved form of tau (c-tau) is acutely
elevated 6h post-injury in the serum of rats receiving a severe CCI. However, tissue levels of
c-tau remained elevated beyond 6h and were significantly increased for at least 7 days postinjury, both in the hippocampus and the cortex (Gabbita et al., 2005).
More diffuse models of injury, such as mild blast TBI, mild rotational TBI and repetitive
closed head injury have shown post-injury increases in serum tau to be sustained for longer
periods of time. Following a single, low-intensity blast TBI in mice, serum tau is
significantly elevated two hours and one day following injury (Ahmed et al., 2015).
However, non-significant elevations in serum tau were sustained for at least one month
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following injury (Ahmed et al., 2015); a time course which parallels findings in mice
receiving a mild blast-injury in which phosphorylated and cleaved forms of neuronal tau
were increased 24h and one month post-injury (Huber et al., 2013). Therefore, increases in
serum tau following blast TBI are likely to be representative of pathophysiological changes
to tau in the brain tissue. Additionally, in rats receiving a mild TBI produced by rotational
acceleration forces, serum tau is significantly elevated for at least 14d post-injury (Rostami
et al., 2012), and in mice receiving repetitive closed head injuries, serum levels of total tau
and phosphorylated tau are significantly elevated one day to one month post-injury, findings
which again parallel increases in cortical phosphorylated tau (Yang et al., 2015).
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In human TBI, increases in serum tau correlate with injury severity (Wang et al., 2016) and
peak two days post-injury (Wang et al., 2016). However, in severe TBI, levels of CSF tau
continue to rise beyond two days, peaking between five and 15 days post-injury (Franz et al.,
2003). In addition to full-length tau, cleaved tau isoforms have also been found in CSF
following severe TBI (Zemlan et al., 2002; Zemlan et al., 1999). Importantly, several studies
show that following severe TBI, levels of tau in the serum, cerebrospinal fluid, and brain
extracellular fluid correlate with outcomes up to one year post-injury (Liliang et al., 2010;
Magnoni et al., 2012; Ost et al., 2006; Wang et al., 2016; Zemlan et al., 2002), suggesting
that in severe TBI, acute increases in peripheral tau may be related to pathologic processes
that contribute to mortality and morbidity.
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The ability of tau to serve as a biomarker for mild TBI in human patients is less clear.
Although serum tau is known to be elevated following pediatric mild TBI (Guzel et al.,
2010), the clinical utility of serum tau as a biomarker for mild TBI has been questioned. For
example, serum tau is unable to distinguish between mild TBI with or without intracranial
lesion (Guzel et al., 2010; Kavalci et al., 2007), and serum levels of c-tau are unable to
predict the development of post-concussive symptoms following mild TBI (Bazarian et al.,
2006; Ma et al., 2008).
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Despite the less than promising results in regard to the value of peripheral tau as a biomarker
for mild TBI, various tau isoforms have been found to be elevated in the plasma, serum, or
CSF of groups at risk for sustaining multiple head injuries, such as athletes and military
personnel. In fact, in male athletes, participation in collision sports is associated with
elevated levels of plasma tau (Di Battista et al., 2016). In boxing, total tau levels are
increased in the CSF for up to ten days and in the plasma for up to six days following a
match, with significantly increased levels being seen in the CSF of players sustaining more
hits to the head (Neselius et al., 2012; Neselius et al., 2013; Zetterberg et al., 2006). In
hockey, total tau is elevated in the serum of concussed players for up to six days following
injury and correlates with duration of post-concussive symptoms (Shahim et al., 2014).
Similarly, caspase cleaved tau (c-tau), a fragment itself capable of perpetuating tau
pathology, is elevated in the serum of hockey players post-concussion, and the tau fragment,
Tau-A, correlates with the number of days it takes concussed players to return to play
(Shahim et al., 2016). Tau-A is generated by cleavage of tau by ADAM-10 (Shahim et al.,
2016), a metalloproteinase which has been shown to be elevated in animal models of TBI
(Warren et al., 2012).
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In addition to acute and sub-chronic time points, increases in peripheral tau have been shown
to be sustained chronically in both athletes and military personnel. Compared to controls, the
serum of symptomatic retired NFL players contains a significantly increased number of tau
positive exosomes, which correlate with cognitive impairment (Stern et al., 2016). Exosomes
are stable cell exocytosed nanovesicles, the content of which is representative of the cell of
origin (Stern et al., 2016). Furthermore, plasma levels of total tau are significantly increased
in military personnel sustaining three or more TBIs and levels correlate with post-concussive
symptoms, despite the majority of participants having sustained TBIs at least 18 months
prior (Olivera et al., 2015).
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Therefore, these studies suggest that in addition to severe TBI, concussions, sub-concussive
hits, and repetitive mild head injuries are sufficient enough to cause acute dissociations of
tau from the microtubules, and that repeat injuries can lead to sustained increases in
peripheral tau. Furthermore, the correlation that tau positive exosomes and sustained plasma
tau levels have with chronic symptoms suggests that increases in peripheral tau may indeed
be representative of brain pathology.

6. TBI, Tau, and CTE - The Animal Models
6.1 Experimental TBI-induced Tau pathology
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Animal models have been used extensively to model TBI and are able to recapitulate several
aspects of human TBI neuropathology and behavioral impairment (Xiong et al., 2013).
Currently, animal models are being used to elucidate the effects of single or repetitive TBI
on acute and chronic tau pathology. Ojo et al. (Ojo et al., 2016) has extensively covered
methodologies, pathologies, and the benefits and challenges of using animals to study
repetitive TBI and CTE. A multitude of factors are purported to influence CTE development
including injury type, injury severity, impact number, impact frequency, age at injury, time
elapsed since injury, genetics, gender, and environment (Ojo et al., 2016). Therefore,
examining the relationship between TBI and CTE in animals is challenging; a difficulty
which is evidenced throughout the literature. For example, while some animal models of
repetitive TBI induce significant increases in tau phosphorylation, others have either found
no significant tau pathology or tau pathology in only single animals (Ojo et al., 2016).
Furthermore, despite increases in phosphorylated and total tau following injury, most studies
fail to recapitulate other pathologic characteristic of CTE such as tangle formation, glial tau,
perivascular tau deposition, and deposition of tau at the depths of sulci, a characteristic
which would be practically impossible to model in the lissencephalic rodent brain (Ojo et
al., 2016).
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The anatomic and physiologic differences between humans and rodents (mice being the
most common animal used in studies of tau) further complicate matters. Anatomically,
human brains contain higher ratios of white to grey matter, higher ratios of glia to neurons,
sulci, gyri, longer myelinated axons, and a denser vascular supply (Ojo et al., 2016). The
ratio of 3R to 4R tau also differs in rodents and in humans. Healthy adult brains express
equal ratios of 3R and 4R tau (Goedert and Jakes, 1990; Ojo et al., 2016), whereas rats and
mice express 4R tau, an isoform which is preferentially phosphorylated and prone to
aggregation, to a much higher degree than 3R tau (Hanes et al., 2009; McMillan et al., 2008;
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Ojo et al., 2016). Additionally, animal models of CTE often depend on the use of transgenic
mice. For example, many of the transgenic mice used to study pathologic tau utilize FTD-17
mutations, such as P301L, which preferentially favor 4R splicing (Ojo et al., 2013; Ojo et
al., 2016). Transgenic tau mice also overexpress tau compared to wild type mice, and are
predisposed to the development of tau pathology (Ojo et al., 2016). In fact, in some CTE
studies, transgenic tau mice are aged and already display tau pathology prior to injury (Ojo
et al., 2013; Ojo et al., 2016).
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Despite the difficulty in using animals to investigate the relationship between TBI, tau and
CTE, important observations have been made. Several pathologic tau isoforms have been
observed in experimental animal models of TBI, including increases in total tau,
phosphorylated tau, cleaved tau, tau oligomers, tau aggregates and other pathologic tau
confirmations. However, animal models of TBI are diverse, ranging from mild to severe,
focal to diffuse, and single to repetitive, which can affect the time course and type of tau
pathology seen following injury.
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Several different models of TBI, including controlled cortical impact injury (CCI), fluid
percussion injury (FPI), and blast injury have shown tau to be increased acutely following
injury. CCI, a focal model of injury which includes aspects of contusion, hemorrhage and
diffuse injury (Hall et al., 2005), results in severity-dependent increases in cleaved tau (ctau), with severe injury inducing significant increases in c-tau beginning at 6h in the cortex
and 48h in the hippocampus, increases which are sustained for at least seven days following
injury and which are attenuated by the neuroprotective drug CsA (Gabbita et al., 2005).
Similarly, following a moderate FPI, a mixed model of focal and diffuse injury (Thompson
et al., 2005), oligomeric and phosphorylated tau are increased acutely: 4h, 24h and 2 weeks
post-injury (Gerson et al., 2016; Hawkins et al., 2013). Mild blast TBI, which encompasses
both the blast wave and rotational acceleration-deceleration forces and results in diffuse
injury, transient axonal injury, and vascular pathology (Courtney and Courtney, 2015;
Kovacs et al., 2014), has also been shown to increase tau acutely following injury. For
example, mild blast TBI increases phosphorylated tau in rat hippocampus 6h post-injury
(Perez-Polo et al., 2015), and a repetitive blast injury consisting of three closely spaced
blasts results in total tau levels being increased 24h post-injury in mouse cerebellum (Arun
et al., 2013).
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Chronic tau pathology has also been observed following blast injury. Tau phosphorylation
and pathologic tau conformations are increased in rat hippocampus and cortex one month
following either a single blast or six blasts spaced 48h apart (Turner et al., 2015).
Furthermore, rats exposed to repeat injury showed evidence of perivascular tau pathology, a
defining feature of human CTE (Turner et al., 2015). Seventy days following a single blast
injury in rats, total tau protein is also increased in several brain regions including the
amygdala, prefrontal cortex and hippocampus; an affect which can be attenuated by
environmental enrichment (Kovesdi et al., 2011). Tau oligomers have also been observed to
develop one month following a single blast TBI (Gerson et al., 2016). In fact, tau oligomers
extracted from rat brains one month following a single blast TBI have prion-like
characteristics, increasing the spread of tau pathology and accelerating the rate of cognitive
decline when injected into brains of transgenic mice overexpressing human tau (Gerson et
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al., 2016). Tau aggregation also occurs following blast TBI, although in a delayed manner.
For example, three months following a single blast injury, rats develop tau aggregates in the
prefrontal cortex and hippocampus that were not yet present one-month following injury
(Sajja et al., 2015).
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Chronic tau pathology has also been detected following closed head injury, another animal
model of diffuse TBI. Similar to blast injury, increases in tau phosphorylation and
pathologic tau conformations have been found one month following a single closed head
injury (Turner et al., 2015). However, other studies have shown a requirement for repeat
injuries in order to induce tau pathology following closed head injury. For example, in aged,
transgenic mice overexpressing human tau and who already showed signs of tau pathology
prior to injury, repeat injury (five injuries space 48h apart) but not single injury, resulted in
increases in cortical and hippocampal tau phosphorylation three weeks post-injury (Ojo et
al., 2013); however, other characteristic CTE pathologies, such as perivascular tau, neuritic
threads and astrocytic tangles, were not seen (Ojo et al., 2013). Similar increases in tau
phosphorylation following repetitive closed head injury occur in wild-type mice. For
example, exposing mice to four closed head injuries spaced three days apart results in
increased tau phosphorylation in the hippocampus and cortex, effects which are sustained
for at least seven days and 30 days, respectively (Yang et al., 2015). Additionally, chronic
increases in tau phosphorylation following repetitive closed head injury have been observed
to occur beyond 30 days. For example, exposing mice to three closed head injuries spaced
24h apart, results in increases in tau phosphorylation in the corpus callosum, cortex,
hippocampus and amygdala six months following injury (Luo et al., 2014). Furthermore,
evidence suggests that the presence of tau following repetitive closed head injury is linked to
the development of pathology following injury. In fact, in a two-hit frontal impact model of
closed head injury, knocking out tau attenuates chronic axonal degeneration and learning
and memory deficits (Cheng et al., 2014).
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Newer models of closed head injury, which also incorporate rotational accelerationdeceleration forces in an attempt to more closely model human concussion, also have
demonstrated increases in tau pathology following injury. In a model termed CHIMERA,
which stands for Closed-Head Impact Model of Engineered Rotational Acceleration, an
impact device is used to deliver a closed head injury to mice while allowing for free rotation
of the head upon impact (Namjoshi et al., 2014). In CHIMERA, two impacts spaced 24h
apart results in increases in tau phosphorylation over the first 48h following injury
(Namjoshi et al., 2014). Chronic increases in tau phosphorylation have also been seen in
similar models. For example, in another combined model of closed head injury and
rotational acceleration, exposing mice to five injuries spaced 24h apart results in increases in
tau phosphorylation for at least 30 days following injury (Kane et al., 2012). Similarly, in a
closed head injury model which allows for head mobility and the use of non-anaesthetized
mice, tau phosphorylation is increased in the cortex, hippocampus, amygdala and dentate
gyrus seven days and one month following single or repetitive (42 injuries) injury (Petraglia
et al., 2014). Furthermore, increases in tau phosphorylation were sustained out to six months
in repetitive injury mice (Petraglia et al., 2014).
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Although less studied in isolation, evidence suggests that rotational acceleration-deceleration
forces themselves are capable of inducing tau pathology. In fact, head restraint during blast
injury is able to attenuate increases in tau phosphorylation, neuroinflammation,
microvascular pathology, neurodegeneration, and learning and memory impairment
(Goldstein et al., 2012). In swine models of rotational head injury, PHF-tau is reported to
accumulate in neuronal perikarya following injury (Smith et al., 1999). Similarly, a model
using air pressure to induce a rotational head injury in mice absent a blast wave, results in
increases in tau phosphorylation two and eight weeks post-injury; however, similar to other
models, additional aspects of tau pathology such as tau aggregation were not seen (Sabbagh
et al., 2016).
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6.1.1 Select Mechanisms of Experimental TBI-induced Tau Pathology—Multiple
animal models of TBI, including diffuse injury, blast injury, closed head injury and
rotational acceleration-deceleration injury, have all demonstrated increases in pathologic tau
following injury. These models of injury also result in widespread damage to axons and
white matter tracts, suggesting the possibility that diffuse axonal damage and pathologic tau
formation are related. In fact, in transgenic mice expressing either human mutant tau, P301S,
or the six isoforms of wild type human tau, a mild repetitive impact-acceleration injury
induces dose-dependent advanced tau hyperphosphorylation and tangle formation ten weeks
following injury (Xu et al., 2015). However, tau pathology only develops in regions of the
brain associated with transient axonal injury; specifically, tau pathology develops in the
retinal ganglion cells as this model induces transient axonal injury to the optic nerve (Xu et
al., 2015). In addition to diffuse axonal injury being capable of inducing tau pathology,
dendritic damage has also been implicated in increased tau phosphorylation. For example, in
rats, epidural cortical compression rapidly results in mechanical disruption of the dendritic
cytoskeleton, resulting in increases in phosphorylated tau, alterations in tau kinase and
phosphatase activity levels, and dendritic remodeling, implying rapid changes to cortical
circuitry that could have long lasting effects on brain function (Chen et al., 2010a).
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Several experimental TBI studies have identified additional mechanisms which also may
contribute to pathologic tau formation. Several studies have observed that increases in tau
phosphorylation following injury are accompanied by alterations in phosphatase or kinase
activity. In FPI, increases in tau phosphorylation twelve weeks post-injury are accompanied
by decreases in expression and activity of the tau phosphatase, PP2A, neurodegeneration and
cognitive impairment, effects which are attenuated by the administration of the PP2A
activator, sodium selenite (Shultz et al., 2015). Similarly, in blast and weight-drop models of
TBI, acute increases in tau phosphorylation coincide with decreases in activity of tissue nonspecific alkaline phosphatase (TNAP), a phosphatase with greater activity towards
phosphorylated tau than PP2A (Arun et al., 2015). Additionally, following CCI in mice,
increases in tau phosphorylation, cognitive impairment and hippocampal degeneration are all
attenuated by administration of lithium, an inhibitor of the tau kinase, GSK-3β (Yu et al.,
2012).
In addition to alterations in tau phosphatase and kinase activity, oxidative stress also has
been observed to coincide with tau pathology following experimental TBI. Exposing mice to
a single blast results in increases in phosphorylated and cleaved tau 24h post-injury in the
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cortex, hippocampus, and cerebellum, increases which are sustained in the hippocampus 30
days post-injury, and which are accompanied acutely by increases in oxidative stress defense
mechanisms in the hippocampus and cerebellum, namely increases in the mitochondrial
anti-oxidant, SOD2 (Huber et al., 2013). Oxidative stress has also been seen to accompany
tau pathology in repetitive models of TBI. In a repetitive blast injury model, exposing mice
to six blasts spaced 48h apart results in increases in pathologic tau, apoptosis, and
impulsivity, effects which are attenuated by administration of the antioxidant, lipoic acid
(Lucke-Wold et al., 2015). Lipoic acid inhibits NOX4, an enzyme increased in CTE brains
which is capable of inducing oxidative stress (Lucke-Wold et al., 2015). Additionally, in a
repetitive mild closed head injury model, exposing mice to three impacts spaced 24h apart,
results in increases in phosphorylated tau, inflammation, and synaptic and cognitive
impairment 30 days post-injury, effects which are attenuated by inhibition of
monoacylglycerol lipase (MAGL) (Zhang et al., 2015). MAGL metabolizes
endocannabinoid 2-arachidonoylgylcerol (2-AG) to prostaglandins and arachidonic acid
(Zhang et al., 2015). Therefore, inhibiting MAGL acts to increase 2-AG, a compound known
for having anti-inflammatory and neuroprotective properties (Zhang et al., 2015), while also
decreasing the 2-AG metabolite, arachidonic acid, which is itself capable of initiating LP
(Bains and Hall, 2012; Hall et al., 2010).
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Experimental TBI has also been shown to increase toxic forms of tau by impairing the
function of the proline isomerase, Pin1. Pin1, converts tau phosphorylated at Thr231 from
the cis isomer to the less toxic trans configuration (Kondo et al., 2015). Phosphorylation of
Pin1 increases following experimental TBI, leading to decreased Pin1 activation and,
therefore, increased levels of the cis isomer (Kondo et al., 2015). Pin1 can also be inhibited
through cysteine oxidation (Chen et al., 2015), an event likely to occur under TBI-induced
oxidative stress conditions. Formation of the cis isomer of phosphorylated tau (cis p-tau) is
reported to be an early pathogenic event in the tauopathy, AD, (Nakamura et al., 2012), and
increases in cis p-tau have been identified in CTE (Kondo et al., 2015), and in experimental
models of severe TBI, repetitive mild TBI (rmTBI) and blast TBI (Kondo et al., 2015). In
fact, six months following rmTBI cis p-tau which developed acutely at the site of injury has
spread to additional brain regions (Kondo et al., 2015). Cis p-tau is suspected of being
neurotoxic. In fact, in an experimental model of severe TBI, administration of a cis p-tau
antibody prevents development and spread of cis p-tau, attenuates disruptions in microtubule
and mitochondrial transport, and improves functional and behavioral outcomes (Kondo et
al., 2015).
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In addition to dysfunction of enzymes and oxidative stress pathways, dysfunctional tau
clearance mechanisms have been observed following experimental TBI. A moderate-severe
closed head injury in mice results in impairment to the glymphatic pathway for at least one
month following injury and correlates with increases in tau phosphorylation (Iliff et al.,
2014). The glymphatic pathway is a perivascular network responsible for CSF recirculation
and clearance of interstitial proteins such as tau and Aβ (Iliff et al., 2014; Iliff et al., 2012).
The glympathic pathway is highly dependent on the protein, perivascular glial aquaporin-4
(AQP4), which is also chronically impaired following experimental TBI (Iliff et al., 2014;
Ren et al., 2013). In fact, knock-out of aquaporin-4 results in increases in tau
phosphorylation, axonal degeneration, neuroinflammation, and behavioral deficits following
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experimental TBI suggesting that chronic glymphatic dysfunction following TBI may
contribute to the development of neurodegenerative tauopathies through impairment of tau
clearance (Iliff et al., 2014).
6.2 Experimental TBI without Tau Pathology
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Although multiple animal models have demonstrated that pathologic tau is increased
following acute TBI, pathologic tau can be sustained chronically following TBI, and several
possible mechanisms that could lead to tau dysfunction following injury, there have been
other animal models which have failed to demonstrate any tau pathology following injury. In
fact, even the use of transgenic mice does not always ensure formation of tau pathology
following experimental TBI. For example, in a repetitive mild closed head injury in which
aged transgenic mice expressing the shortest form of human tau (T44) received a total of 16
injuries over the course of four weeks, only 1 in 9 mice developed neurofibrillary tangles
and cerebral atrophy (Yoshiyama et al., 2005). However, except for the individual mouse
displaying tau pathology, this model was also unable to induce any cognitive deficits six
months post-injury (Yoshiyama et al., 2005).
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Several additional examples demonstrate the difficulty of modeling CTE in rodents. In a
mouse study that paralleled several clinical and pathological aspects of human TBI, a single
mild closed head injury resulted in pathology and behavioral deficits that remained static
over time, whereas repeat injury (five injuries spaced 48h apart) resulted in progressive
neuroinflammation, white matter degradation, and behavioral impairment over 6-18 months
following injury despite no increases in tau phosphorylation (Mouzon et al., 2014).
Similarly, in a mouse model combining impact and rotational acceleration, repeating injuries
on a daily or weekly basis resulted in increases in astrogliosis and cognitive impairment up
to one year following injury, but no increases in tau phosphorylation (Mannix et al., 2013).
A lack of tau pathology following rmTBI has also been seen at more acute time points. For
example, in a mouse model of repetitive mild closed head injury, five impacts spaced 24h or
48h apart results in motor and cognitive deficits, axonal degeneration and astrogliosis,
particularly in the visual system, ten weeks following injury; however, increases in
hyperphosphorylated tau were not seen (Bolton Hall et al., 2016). Similarly, although
exposing mice to five injuries spaced 24h apart results in increased hemorrhagic lesions,
diffuse axonal injury, neurodegeneration, and astrogliosis 24h post-injury compared to
intervals spaced 48h apart, neither injury paradigm results in increased tau phosphorylation
(Bolton and Saatman, 2014).
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In summary, use of animal models to study CTE and the development of chronic tau
pathology following experimental TBI is complicated by a multitude of factors including
heterogeneity of human injury, heterogeneity of individuals, and anatomic and physiologic
differences between humans and rodents. Although individual studies have failed to
recapitulate all aspects of CTE pathology, numerous studies have confirmed the ability of
experimental TBI to induce acute and chronic tau pathology, and the ability of repetitive
injury to exacerbate that pathology. Furthermore, animal models have confirmed
mechanisms suspected of contributing to tau pathology following injury such as tau kinase
and phosphatase dysfunction and induction of oxidative stress pathways, and identified
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additional mechanisms that possibly contribute to tau dysfunction following injury such as
Pin1 inhibition and dysfunction of the glympathic pathway.

7. Conclusions and Possible Neuroprotective Strategies to Prevent or
Interrupt the Progression of CTE
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Traumatic brain injury results in a secondary injury cascade that includes processes such as
calpain and caspase activation, mitochondrial and ER dysfunction, increases in oxidative
stress including generation of peroxynitrite which trigger, lipid peroxidation and LP-derived
breakdown products, most notably the neurotoxic aldehydes 4-HNE and acrolein, and
neuroinflammation. While these post-TBI biochemical and cellular pathophysiological
events begin within the first minutes, days and hours post-TBI, there is evidence that some
of these events may persist into the chronic injury phase exerting negative effects on
recovery months and perhaps years after the single of repetitive TBI episodes and
contributing to age-related neurodegenerative diseases. Similar processes occur in
neurodegenerative tauopathies and many have been shown to occur upstream, downstream,
and in a circular cascade with tau dysfunction (Figure 9). A history of TBI, particularly
repetitive, is a risk factor for both CTE and AD; therefore, it is possible that several of the
above mentioned pathologies, which occur acutely following TBI, lead to chronic
neurodegeneration and tau dysfunction. However, the apparent complexities of the
mechanistic link between acute post-traumatic secondary injury processes and their
contribution to chronic outcomes is yet to be un-raveled. Nevertheless, since CTE has only
been documented in individuals with histories of repetitive, and perhaps even single, TBIs, it
is entirely possible that early initiation of neuroprotective treatments that will effectively
inhibit the acute, subacute and early chronic secondary injury phases will lessen the
development of the tauopathy that is the key neuropathology seen in CTE. While a single
neuroprotective approach might be able to significantly attenuate the progressive brain
damage in CTE, since a variety of cellular dysfunctions can lead to tau dysfunction, which
can in turn lead to several cellular dysfunctions, it is likely that a multi-mechanistic
neuroprotective combinational approach to CTE prevention and interruption will be needed.
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2-AG

2-arachidonoylglycerol

3-NT

3-nitrotyrosine

4-HNE

4-hydroxynonenal

Ach

acetylcholine

AChEI

acetylcholine esterase inhibitor

AD

Alzheimer's disease

ADAM-10 A disintegrin and metalloproteinase domain-containing protein 10
ANT

adenine nucleotide translocator

APP

amyloid precursor protein

AQP4

aquaporin-4

CCI

controlled cortical impact injury

CDK5

cyclin-dependent kinase 5

CHIMERA closed-head impact model of engineered rotational acceleration
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COX

cytochrome oxidase

CsA

cyclosporine A

c-tau

cleaved tau

CTE

chronic traumatic encephalopathy

CX3CL1

C-X3-C motif ligand 1 / fractalkine

CX3CR1

CX3C chemokine receptor / fractalkine receptor

DRP1

dynamin-related protein

ERAD

ER-associated degradation

ERK

extracellular-regulated kinase

FPI

fluid percussion injury

FRET

fluorescence resonance energy transfer

FTD

frontotemporal dementia

GSK-3β

glycogen synthase kinase-3β
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hTau

human tau

IFN

interferon

IL

interleukin

JNK

c-Jun-terminal kinase

LP

lipid peroxidation

LPS

lipopolysaccharide

MAGL

monoacylglycerol lipase

MAP

microtubule-associated protein

MAPK

mitogen-activated protein kinase

MAPT

microtubule-associated protein tau

mPTP

mitochondrial permeability transition pore

mtNOS

mitochondrial nitric oxide synthase

NADPH

nicotinamide adenine dinucleotide phosphate

NFT

neurofibrillary tangle

NOX4

NADPH oxidase 4 gene

PHF

paired helical filament

PIN1

peptidyl-prolyl cis-trans isomerase NIMA-interacting 1

PN

peroxynitrite

PP2A

protein phosphatase 2

PSD-95

postsynaptic density 95

PSP

progressive supranuclear palsy

p-tau

phosphorylated tau

rmTBI

repetitive mild TBI

RNS

reactive nitrogen species

ROS

reactive oxygen species

SOD2

mitochondrial superoxide dismutase 2, manganese-dependent superoxide
dismutase

TNAP

tissue non-specific alkaline phosphatase

TBI

traumatic brain injury
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TDP-43

transactive response DNA-binding protein

TLR4

toll-like receptor 4

UPR

unfolded protein response
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•

Chronic traumatic encephalopathy (CTE) is a recently described
neurodegenerative tauopathy that is a chronic sequela of traumatic brain
injury (TBI).

•

CTE occurs predominantly after repeated episodes of mild TBI in athletes
involved in contact sports or in military combatants exposed to single or
repetitive explosive blast-injuries.

•

This review discusses the possible involvement of the well characterized postTBI pathophysiological mechanisms in the pathogenesis of tau protein
deposition that is distinctly characteristic of CTE.

•

The analysis of the possible interactions of TBI secondary injury with CTE
tauopathy has suggested several neuroprotective approaches that might serve,
either singly or in combination, to limit the development of CTE.
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Figure 1. Interplay between TBI pathophysiology and mechanisms of pathologic tau formation
demonstrating several cyclic relationships between the two
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TBI induces traumatic axonal injury (TAI), neuroinflammation, increases in intracellular
Ca++, shearing of blood vessels, and tau hyperphosphorylation. TAI causes microtubule
detachment of tau and tau mislocalization. Ca++ uptake by the endoplasmic reticulum (ER)
and mitochondria leads to organelle dysfunction, including increases in ROS, RNS, and
peroxynitrite (PN), initiation of lipid peroxidation (LP), and 4-HNE and acrolein formation.
Hemorrhage-derived Fe++ catalyzes formation of reactive species and LP. 4-HNE and
acrolein bind mitochondrial proteins, exacerbating dysfunction and generation of reactive
species. Dysfunctional mitochondria enhance ER dysfunction, release cytochrome c, which
activates caspases, and extrude Ca++ into the cytosol, which activates calpain. Calpain
cleaves cytoskeletal proteins (e.g. spectrin) resulting in cytoskeletal degradation.
Neuroinflammation, ER dysfunction, ROS/RNS/PN, mitochondrial dysfunction, caspase/
calpain activation, and cytoskeletal degradation contribute to formation of pathologic tau
(e.g. post-translational modification, conformational change, aggregation, etc.). In return,
pathologic tau contributes to neuroinflammation, ER dysfunction, generation of
ROS/RNS/PN, mitochondrial dysfunction, caspase activation and cytoskeletal degeneration.
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Figure 2. Select pathways demonstrating the role of oxidative stress in formation of tau
pathology
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TBI induces mitochondrial dysfunction, resulting in increased oxidative stress, which in
turn, exacerbates mitochondrial dysfunction. Proteases downstream of mitochondrial
dysfunction cleave tau, forming truncated tau (t-tau), which in turn, exacerbates
mitochondrial dysfunction. Experimental tau overexpression induces mitochondrial and
peroxisome dysfunction. Peroxisome dysfunction exacerbates oxidative stress and is
enhanced by oxidative stress. Oxidative stress increases tau kinases activity (GSK-3β, JNK)
and decreases tau phosphatase activity (PP2A), resulting in hyperphosphorylation of tau,
which decreases tau binding of microtubules (red X), leading to tau aggregation, which is
enhanced by oxidative stress itself.
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Figure 3. Mechanisms by which peroxynitrite leads to formation of tau pathology
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TBI-induced mitochondrial dysfunction generates peroxynitrite (PN), which in turn,
exacerbates mitochondrial dysfunction. PN nitrates or oxidizes tau forming 3,3′-dityrosine
or disulfide crosslinks, respectively. Crosslinked tau induces tau oligomerization,
aggregation and filament formation. Disulfide crosslinked tau also decreases microtubule
assembly. PN increases the tau kinase, p38 MAPK. PN-derived NO•2 increases the tau
kinase, GSK-3β, through nitration of the GSK-3β upstream regulator, p85. Increased tau
kinase activity results tau hyperphosphorylation which decreases binding of tau to
microtubules (red X). NO•2 directly nitrates tau at the 3 position of tyrosine, generating
tau-3NT. Tau-NT has decreased microtubule binding properties (red X) and inhibits tubulin
assembly. Tau-3NT is preferentially degraded by the proteasome, an organelle that's function
is inhibited by PN, resulting in build-up and aggregation of tau-NT.
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Figure 4. The role of 4-hydroxynonenal (4-HNE) and acrolein (ACR) in formation of tau
pathology

TBI induces lipid peroxidation (LP). Overexpression of P301L mutant also increases LP as
measured by the LP-derived, malondialdeyde (MDA). LP results in the formation of the
neurotoxic aldehydes, 4-HNE and ACR, which covalently bind proteins, including tau,
causing protein dysfunction. ACR increases activity of the tau kinases, GSK-3β and p38
MAPK, and 4-HNE-modified tau inhibits alkaline phosphatase, resulting in
hyperphosphorylation of tau, 4-HNE modified-tau, and ACR modified-tau, which decreases
binding of tau to the microtubules (red X), leading to conformational changes, aggregation,
and filament formation. Paired helical tau filaments are extensively modified by 4-HNE and
ACR.
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Figure 5. Mechanisms by which endoplasmic reticulum (ER) stress and dysfunction can lead to
formation of tau pathology
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Following TBI increases in intracellular Ca++, derived extracellularly or from dysfunctional
mitochondria, induce ER stress. ER stress increases activity of the tau kinase, GSK-3β,
resulting in tau hyperphosphorylation, which decreases binding of tau to microtubules (red
X). ER stress results in the buildup of misfolded and unfolded proteins, including tau, both
directly and through inhibition of ER-associated degradation (ERAD). Tau itself inhibits
ERAD through associations with the ERAD heterocomplex. ERAD and buildup of
misfolded and unfolded proteins activate the unfolded protein response (UPR), which in
turn, activates ERAD. The UPR results in increases in tau phosphorylation, which in turn,
activate the UPR. UPR activation increases neurotoxicity and behavioral impairment and
decreases synthesis of proteins, including synaptic proteins. ER stress activates the protease,
caspase-3, resulting in tau truncation (t-tau) and increased neurotoxicity. Alzheimer's
disease-derived microsomes contain ER fragments and ribosomes which strongly associate
with oligomeric tau, resulting in decreased RNA translation and decreased protein
concentrations.
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Figure 6. The role of calpain in the formation of pathologic tau
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TBI-induced increases in intracellular Ca++ derived extracellularly or from dysfunctional
mitochondria and ER, activate the protease calpain. The endogenous calpain inhibitor,
calpastatin, is decreased in tauopathies such as Alzheimer's disease. Calpain cleaves tau into
35kD and 17kD fragments. The 17kD tau fragment forms prior to increases in tau
phosphorylation and may directly enhance tau phosphorylation (dotted arrow). Calpain
induces activation of the tau kinase, ERK, resulting in hyperphosphorylation of tau, which
decreases binding of tau to microtubules. 17kD has a decreased affinity for microtubule
binding (red X) and may be neurotoxic.
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Figure 7. Mechanisms in which caspases play a central role in the formation of pathologic tau
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Following TBI, caspases are activated downstream of ER dysfunction and mitochondrial
release of cytochrome c. Overexpression of P301L tau or 4R also induce caspases activation.
Caspases, including caspase-3, cleave tau at Asp421, but N-terminal caspase-cleavage also
occurs (NH-tau). Caspases-cleaved tau can further exacerbate mitochondrial and ER
dysfunction. Asp421 is preferentially degraded by autophagy, therefore, impairment to
autophagy results in accumulation of Asp421 tau. Asp 421 tau leads to enhanced tau
polymerization and phosphorylation, resulting in decreased binding of tau to microtubules
(red X) and increased aggregation and filament formation. Caspase activation and Asp421
expression lead to apoptosis. Asp421 precedes cognitive impairment.
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Figure 8. Proposed role for microglia in the formation of pathologic tau
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TBI and experimental tau overexpression activate microglia. Microglia can be activated
through decreases in the microglia receptor, CX3CR1, and increases in the neuronallyderived ligand, CX3CL1, which is elevated following TBI and experimental tau
overexpression. Microglial secretion of IL-6 increases tau mRNA and protein expression.
Microglial secretion of IL-1β and IL-6 increases tau kinase activity (p38 MAPK and cdk5),
as does the presence of the cytokine IFN-γ (GSK-3β), resulting in tau hyperphosphorylation,
which decreases binding of tau to microtubules (red X), and microglial phagocytosis of
hyperphosphorylated tau. Microglia spread tau in a prion-like manner through phagocytosis
and exocytosis. Hyperphosphorylated tau induces microglia degeneration, resulting in
decreased immunosurveillance and increased neurodegeneration. The microglia-derived
cytokine, TNF, activates NADPH Oxidase, increasing ROS and formation of tau aggregates.
The presence of phosphorylated tau enhances the effect of activated microglia on
neurodegeneration, caspase-3 activation, and behavioral impairment. Activated microglia
induce autophagy, resulting in autophagic degradation of tau.
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Figure 9. Simplified schematic demonstrating proposed pathological mechanisms that can
contribute to CTE development and pathologic mechanisms that can be exacerbated by CTE

Examples of pathologic tau include hyperphosphorylation, nitration, oxidation, aggregation,
filament formation, etc. For simplicity, relationships between pathologic mechanisms are not
included in this figure, but are detailed elsewhere (Fig 1– 8).
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